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ABSTRACT 
Syzygium cumini is a well known bioactive plant which has been widely used for the 
treatment of various diseases in traditional and folk medicine. The present investigation was 
aimed to determine the tocolytic activity of the aqueous seed extract of Syzygium cumini 
(AESC) in animal models. The in vitro antioxidant activity of AESC was evaluated by DPPH 
and ABTS radical scavenging assay which showed the hydrogen donating and free radical 
scavenging activity of extract that aids in the prevention of preterm labour. In vivo tocolytic 
activity of AESC was evaluated. Group I was given normal saline, Group II oxytocin (1 IU) 
i.m, Group III atosiban (6mg/kg) i.p, Group IV AESC (200mg/kg) p.o and Group V AESC 
(400mg/kg), p.o. AESC shows significant reduction in the rate of preterm labour which was 
comparable with the standard treated group as well as the normal group. The level of in vivo 
antioxidant parameters such as catalase, SOD, and GSH were restored in the treated group 
compared to the control group. The study reveals that the extracts have been able to increase 
the endogenous antioxidant enzyme activities while reducing the lipid peroxidation. The 
AESC was subjected to pharmacological testing in vitro on a piece of isolated rat uterus 
previously pretreated with estradiol valerate, concentrations used were 25 mg/ml and 50 
mg/ml. The concentrations (25 mg/ml) and (50 mg/ml) produce 50.9 % and 72.7 % inhibition 
respectively. In conclusion, the results indicate the presence of active principles in the 
aqueous seed extract of Syzygium cumini which may be responsible for the tocolytic activity. 
 
Key words: Syzygium cumini, Tocolytic activity 
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1. INTRODUCTION 
Plants have been of great importance to mankind due to their medicinal as well as 
nutritional properties. In 1985, World Health Organization (WHO) estimated that around 
80% of the population depends on medicinal plants for their primary healthcare needs in 
developing countries. Medicinal plants encompass some secondary metabolites like 
alkaloids, glycosides, saponins, essential oils, bitter principles, tannins and mucilages in 
different parts of the plant which can cure various illnesses in humans and other animals. 
Epidemiological studies indicate that increased intake of leafy vegetables is associated 
with decreased risk of cancers, cardiovascular disease, cataract and other age-related 
diseases. [1] 
Plants have been the source of a wide variety of current drugs which are available 
in the market today. Natural products, commonly termed as ‘secondary metabolites’ are 
an essential, reputable source of successful drug leads which originate from Earth’s bio-
diverse flora and fauna. [2] All cultures since long time use herbs as a proficient source of 
medicines. According to WHO, most of the human population still use plants as crucial 
remedial agents in the primary health care system. Even then there are a lot many plants 
and herbs that still remain concealed and are not been studied yet. It has been estimated 
that some 80% of the world’s residents rely predominantly on the traditional medicines 
for the health care requirements and the traditional system mainly utilizes the plant 
extracts or their active ingredient. [3] 
The need of herbal medicines are presently rising every day. About 500 plants 
with medicinal value are mentioned in ancient literature and around 800 plants have been 
used in indigenous systems of medicine. India is an infinite depository of medicinal 
plants that are used in traditional medical therapies. The use of herbal medicine fetching 
recognition due to the side effects and toxicity of allopathic medicines. This led to haste 
rise in the number of herbal drug manufactures. Herbal medicines as the chief therapy in 
traditional system of medicine have been used in medical practices since the distant past. 
The practices persist today as its biomedical benefits as well as place in cultural attitude 
in several parts of world and have made a great involvement towards maintaining human 
wellbeing. India has large number of plant species around the world. There are estimated 
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to be roughly 25,000 successful plants-based formulations, used in folk medicine and 
known to rural communities in India. There are about 1.5 million practitioners of 
traditional medicinal system using medicinal plants in preventive, promotional and 
curative areas. [4] 
Although several allopathic drugs are available, number of reports also stated 
their detrimental side effects on body’s functioning. Therefore, plant-based therapy is 
supposed to be more reliable. Plant parts and their extracts are potential agents for the 
management and treatment of oxidative stress-induced diseases. Because these 
medicines are not only economic and affordable but are also safer and are extensively 
using as effective medication. [5] 
Herbal plants play an input role in the human physical condition. About 80% of 
the world populations rely on traditional medicine which is based on medicinal plants. 
Herbal drugs have gained significance in recent years because of their efficacy, low cost 
and effectiveness. These drugs are used as either single plant extracts or fractions or 
mixtures of extracts from different plants. These plant extracts are standardized for their 
safety and efficacy. [6] 
PRETERM LABOUR 
Preterm delivery is defined as the birth occurring before 37weeks of gestation or 
before 259 days from the last menstrual period. Prematurity is multifactorial and its 
incidence has increased during the last decade in most occidental countries, due to 
increased risk factors responsible for elective prematurity. [7] 
 
The incidence of preterm birth (PTB), or delivery at <37 weeks, continues to 
increase and it accounts for about 75% of all neonatal mortality and morbidity. All 
physicians agree the fact that preterm delivery (PTD) following preterm labor (PTL) 
involves frequent uterine contractions which dilates the cervix. Contractions which do 
not encounter that rate of recurrence or contractions lacking any cervical change several 
hours after uterine activity starts are called as uterine irritability, or false labor. The 
contractions which are having no effect on the cervix are never called preterm labor. In 
order to postponement or prevent PTD, detection of true uterine contractions (cervical 
dilatation <4 cm) should be done sufficiently early, to allow reasonable success of 
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tocolytic drugs which can result in significant pregnancy maintenance. Sometimes, 
painful, irregular uterine contractions can also be associated with false labor or uterine 
irritability and even when they are strong, much less than 50% are perceived by patients. 
PTL can be acute (abruptly going from normal contraction frequency of 1-2/hr on 
average to >8 ctx/hr) or gradual (over days). [8] 
 
The mechanisms for preterm labour are still uncertain. It can be associated either 
with a premature activation of the physiological contracting process or with a 
pathological factor accountable for uterine contractions, leading to preterm delivery. 
Uterine over expansion due to multiple pregnancies or polyhydramnios, placental 
ischaemia, cervical disease, immunologic and allergic phenomenon, decidual or 
retroplacental haemorrhage, fetal endocrine activation and inflammatory processes are 
among the known pathways for preterm labour. Elective prematurity due to maternal or 
foetal conditions is becoming a significant cause for preterm labour. Tocolytic drugs that 
are available till date are directed towards only to the effects and not to the causes of 
preterm labour. 
 
Tocolysis aims to inhibit uterine contractions and also to allow a safe transfer of 
the pregnant patient to a tertiary care centre. It gives the opportunity to take 
corticosteroids for preventing neonatal risks associated with prematurity. 
Risk factors for preterm birth 
Genetic factors can influence preterm birth. Women whose mothers and sisters 
have had a preterm delivery are more likely to have a chance of giving birth prematurely 
which means that a family history of preterm birth is a key risk factor. There exist a 
small but significant association between the paternal genome to preterm labor; this is 
maybe because of the effect of paternally contributed fetal genes, as confirmed by 
isolation analyses and twin studies. Rates of preterm birth in the precise ethnic groups, 
with genetic variation arising from geographic history, also indicate a role for genetics in 
preterm birth. For example, a higher occurrence of preterm birth has been established 
when either the mother or father is an African American. Several studies point out that 
environmental risk factorsare not sufficient to explain racial differences in preterm birth. 
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These population based findings indicate a role for genetic variation in the timing of 
human birth and the risk for prematurity. [9] 
Mechanisms of Tocolysis 
Myometrial contractility is a complex procedure based on myocytes function. It 
involves the presence of many ions channels, hormonal receptors, intercell gap junctions, 
and regulatory proteins such as oxytocin, endothelin, tachykinin, and angiotensin. For the 
uterine smooth muscle contraction, the increase of intracellular calcium concentration is 
necessary. 
As shown on Figure 1, uterine relaxation can be obtained by interfering with an 
intracellular messenger which is responsible for contractile proteins effects. The tocolytic 
drugs include β adrenergic receptor agonists, nitric oxide (NO) donors, magnesium 
sulphate and calcium channel blockers. Another pathway involves the inhibition of 
contracting factors synthesis or its effects. By interfering with endogenous myometrial 
stimulators, atosiban, an oxytocin receptor antagonist and prostaglandin-synthetase 
inhibitors have this result. [7] 
 
 
Figure 1: Mechanisms of action for tocolytics. 
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Types of Tocolytic Treatment 
β Adrenergic Receptor Agonists: Selective β 2 agonists such as ritodrine and 
salbutamol have been used in clinical practice for preterm labour since in the early 
1980s.The intracellular cyclic AMP concentration was made weaken by these drugs and 
facilitate myometrial relaxation. These agents were more efficient than placebo for 
delaying preterm birth for two days which have been reported by randomized controlled 
studies and meta-analysis. Unfortunately, no benefit for long-term (tocolytic effect 
restricted to 7 days) and perinatal mortality and morbidity rate was found with these 
drugs. Furthermore, there are Significant maternal side effects such as tachycardia, 
dyspnoea, hypokalemia, hyperglycemia, and chest pain were reported even with selective 
β 2 adrenergic receptor agonists. In conclusion, regardless of their efficiency, β 2 agonist 
ssafety profile is a real concern responsible for therapy discontinuation and choosing 
substitute tocolytic drugs. [10] 
NO Donors: NO is a potent vasodilator which is synthesized during an amino 
acid oxidation process catalyzed by NO synthase. It is present in myometrial NO Donors 
cells and by interaction with guanylyl cyclase, it increases cGMP content. There is a 
direct relation between NO production and uterine relaxation. Transdermal nitroglycerin 
administrations have a better effect than placebo on delaying delivery for two days. Its 
outcome was similar to ritodrine. NO is not used in clinical routine as there is no large 
randomized studies available. [11] 
Magnesium Sulphate: The relaxant effect of Magnesium sulphate in vivo and 
invitro on human uterine contractility has been widely reported. Since magnesium is a 
calcium antagonist, it decreases calcium intracellular concentration and inhibits 
contraction process. There were concerns about fetal protection as the drug is crossing 
the placenta. In some trials using Magnesium sulphate treatment at high dosage, there 
were reports of an increased risk of perinatal death and neonatal adverse effects together 
with neurological and metabolic disorders. It can also affect maternal neuromuscular 
system. There is a high toxicity risk ensuing in respiratory depression and disappearance 
of reflexes, over a serum concentration of 9mg/Dl. There is no evidence any more to 
advise this drug as a first-line tocolytic agent. However, it was reported to have a 
neonatal neuroprotective effect when administered prophylactically at low dose, in a 
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randomized multicentre trial but this effect should be confirmed in the next future on 
large randomized controlled studies. [12] 
Prostaglandin synthase inhibitors: For converting arachidonic acid to 
prostaglandins, prostaglandin-synthase or cyclooxygenase (COX) isoforms COX-1 and -
2 are necessary enzymes. By enhancing myometrial gap junction and rising intracellular 
calcium concentration prostaglandins are well-known uterine contraction inducers. In 
studies and in a recent meta-analysis, Indomethacin a nonspecific COX inhibitor has 
been reported to be a capable tocolytic drug compared to placebo, significantly delaying 
preterm delivery. It can be administrated via rectally or orally. Due to fetal ductus 
arteriosus closure risk and decreased urine production accountable for 
oligohydramniosits use should be controlled in duration and limited to pregnancies 
below 32 weeks. Maternal side effects including gastric ulcer or asthma recurrence have 
been reported with these treatments. COX-2 inhibitors such as nimesulide or rofecoxib 
have been studied in animals but not yet in humans and are not recommended for 
preventing preterm labour in clinical practice. In conclusion, indomethacin is a 
competent tocolytic drug without any severe adverse drug reactions and is even indicated 
for short term effects during the second trimester of pregnancy. [13] 
Oxytocin Receptor Antagonists: These agents are in competition with the 
myometrial and decidual oxytocin receptors. The only drug now used in clinical practice 
is atosiban. It blocks the intra cytoplasmic calcium release associated with contractions 
and down regulates prostaglandin synthesis. A comparable tocolytic effect but fewer 
adverse effects with atosiban were demonstrated in a first multicentric randomized trial 
comparing atosiban and ritodrine. 
Because of its low side effects profile atosiban is widely used in clinical practice. 
A german meta-analysis based on 6 randomized trials, among them 3 double blind 
studies, confirmed a comparable tocolytic action for atosiban and β adrenergic receptor 
agonists. A significantly low incidence of adverse effects is reported. Furthermore, when 
compared to continuous fenoterol administration controls. Cost saving in terms of 
hospital length and extra tests for excluding morbidity causes is found for the atosiban 
treated patients. In conclusion, atosiban seems to be an ample therapeutic choice for 
effective tocolysis with a low fetal and maternal adverse effects profile. [14] [15] 
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Calcium-Channel Blockers: Calcium ions transfer through the myometrial cell 
membrane are interfered by these agents. They cause decrease in the intracellular free 
calcium concentration and stimulate myometrial relaxation. At a daily dose of 30–60 mg 
nifedipine is the most commonly used drug for preterm labour inhibition. 
Unfortunately, there is no placebo-controlled study available to confirm it. 
Decreased number of deliveries within 7 days following treatment and also, a reduced 
occurrence of neonatal respiratory distress syndrome was reported in a Cochrane 
Database review meta-analysis published in 2003. A recent systematic review based on 
26 trials and 2179 patients confirms a higher effectiveness and a lower side effects 
incidence in the nifedipine group compared to β adrenergic receptor agonists-treated 
patients group. With an easy oral route of administration, low neonatal complications 
rate and fewer adverse effects nifedipine can be confirmed as an efficient tocolytic 
agent.. However, as they may be a risk of pulmonary oedema and cardiac failure, it 
should be used with caution in patients with compromised cardiovascular condition. [16] 
Progesterone and 17-α-Hydroxyprogesterone Caproate: Progesterone a 
steroid hormone is secreted by the corpus luteum and also by the placenta after 8 weeks 
of gestation. It has a physiological consequence on uterine quiescence which is mediated 
by a direct effect on intracellular calcium concentration and prostaglandin synthesis. 
Several randomized trials in patients at risk treated either with weekly intramuscular17-
α-hydroxy progesterone caproate or daily vaginal micronized progesterone from 24 to 34 
weeks reported a notably reduced incidence of preterm birth. But these treatments 
showed less or no benefit in terms of perinatal mortality and morbidity. Fewer side 
effects such as sleepiness and headaches were seen with the vaginal route of 
progesterone administration. Even though these treatments appear effective in patients 
with previous history of preterm birth or with a short cervix, it is essential to gather 
additional data in large randomized controlled trials for confirming its possible benefit in 
the prevention of preterm delivery. [7] 
 
Antibiotics: Infection is one of the causal factors of preterm labour with an 
incidence of 20–40%, especially before 30 weeks. Antibiotics use for preventing preterm 
labour has been mostly studied. The prophylactic administration of antibiotics is not 
recommended as there is little proof of benefits in cases such as the presence of preterm 
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labour with whole membranes. But a meta-analysis based on 22studies including more 
than 6000 patients, shows a significant reduction of preterm delivery and 
chorioamnionitisrate in the treated group, if there is a preterm rupture of the membranes 
(PROM). Neonatal complications were also seemed to be lesser in this population. In 
bacterial vaginosis associated with pregnancy, antibiotics were found to eliminate 
infection but they showed no effect on the incidence of preterm delivery. In conclusion, 
antibiotics can be used only when preterm labour is only due to PROM. [17] 
 
ANATOMY AND PHYSIOLOGY OF UTERUS 
The uterus is the most important female reproductive sex organ of humans and 
also in most other mammals. The lower end of the uterus, the cervix, opens into 
the vagina, while the other end, the fundus, is linked to the fallopian tubes in case of 
humans. It is inside the uterus that the fetus develops during gestation period. In 
the embryo, the uterus develops from the paramesonephric ducts which then combines 
into a single organ known as a simplex uterus. 
 
Structure 
The uterus is located within the pelvic region  and more or less overlying 
the bladder, and in front of the sigmoid colon region. The shape of human uterus is 
somewhat pear-shaped and about 7.6 cm (3 in.) long, 4.5 cm broad (side to side) and 
3.0 cm thick. The weight of a typical adult uterus is almost about 60 grams. 
Anatomically the uterus can be divided into four regions: The fundus, corpus 
(body), cervix and the internal os. The cervix protrudes into the vagina. The uterus is 
detained in place within the pelvis by ligaments which include the pubocervical, 
transverse cervical ligaments or cardinal ligaments, and the uterosacral ligaments. It is 
enclosed by a sheet-like fold of peritoneum, which is the the broad ligament.  
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Figure 2: Diagram showing regions of the uterus 
 
Histological Structure 
The fundus and body of the uterus are composed of three tissue layers; 
 Peritoneum: A double layered membrane, continuous with the abdominal peritoneum, 
also called as the perimetrium. 
 Myometrium: The thick smooth muscle layer and the cells of this layer undergo 
hypertrophy and hyperplasia during pregnancy in preparation to force out the fetus 
during birth. 
 Endometrium: An inner mucous membrane lining the uterus. It can be further 
subdivided into 2 parts – the stratum basalis and the stratum functionalis: 
Deep stratum basalis: It is not shed at menstruation and it changes little throughout the 
menstrual cycle. 
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Superficial stratum functionalis: It becomes secretory in response to progesterone and 
proliferates in response to oestrogens. It is shed during menstruation and regenerates 
from cells present in the stratum basalis layer. 
Ligaments 
The main support for the uterus is provided by the tone of the pelvic floor. Some 
ligaments provide further support, which secures the uterus in place. 
They are: 
 Broad Ligament: This is a double layer of peritoneum which attaches the sides of the 
uterus to the pelvis. It acts as a mesentery for the uterus and helps to maintain it in 
position. 
 Round Ligament: A remnant of the gubernaculum extending from the uterine horns to 
the labia major through the inguinal canal. The anteverted position of the uterus is 
maintained by this ligament. 
 Ovarian Ligament:  It connects the ovaries to the uterus. 
 Cardinal Ligament:  It is located at the bottom of the broad ligament; the cardinal 
ligament extends from the cervix to the lateral pelvic walls. It contains the uterine 
artery and vein. 
 Uterosacral Ligament: It extends from the cervix to the sacrum and provides support 
to the uterus. 
© 2015- 
Position 
The uterus is positioned in the center of the pelvic cavity in frontal plane (due 
to ligamentumlatum uteri). The fundus does not exceed the lineaterminalis, and also the 
vaginal part of the cervix does not extend below interspinal line. The uterus is movable 
and moves posteriorly under the pressure of a full bladder, or anteriorly under the 
pressure of a full rectum and if both are full, it moves upwards. Increased intra-
abdominal pressure pushes it downwards. The mobility is conferred to it by musculo-
fibrous apparatus which consists of suspensory and sustentacular part. Under normal 
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conditions the suspensory part keeps the uterus in anteflexion and anteversionand keeps 
it "floating" in the pelvis. 
The changes of the position of the uterus due to pathological conditions are: 
 retroflexion ˗ if the uterus is fixed 
 hyperanteflexion – slanted too forward 
 anteposition, retroposition, lateroposition – these are the situations when the 
entire uterus is moved which is caused by parametritis or tumors 
 elevation, descensus, prolapsed of the uterus 
 rotation (the entire uterus rotates around its longitudinal axis), torsion (only the 
body of the uterus rotates around) 
 inversion 
Women may have the symptoms of pain during sexual contact, pelvic pain during 
menstruation, minor incontinence, urinary tract infections, fertility difficulties and 
difficulty using tampons in cases where the uterus is "tipped", also called as retroverted 
uterus. 
Blood supply 
Arterial blood both from the ovarian artery and uterine artery is supplied to the 
uterus. From anastomosis of these two arteries, another anastomotic branch may also 
provide blood to the uterus 
Nerve supply 
T11 and T12 are afferent nerves supplying uterus. Parasympathetic supply is 
from second, third and fourth sacral nerves. Sympathetic supply is from hypogastric 
plexus and ovarian plexus. 
Development 
Bilateral Mullerian ducts form during the early fetal life. In males, MIF secreted 
from the testes results in their weakening. In females, these ducts give rise to 
the fallopian tubes and the uterus. In humans, the formation of single uterus occurs when 
the lower segments of these two ducts joins together; however, in cases of uterine 
deformities this development may sometimes get troubled. Due to various degrees of 
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fusion of the two mullerian ducts, there is the formation of different uterine in various 
mammals. 
Functions 
 By directing blood flow to the pelvis and ovaries, and also to the 
external genitals, including the vagina, labia, and clitoris. Uterus play an important role 
in sexual response. 
A fertilized ovum which passes through the utero-tubal junction from 
the fallopian tube is accepted by the uterus, which is considered as its main reproductive 
function. The ovum divides to become a blastocyst, which implants into 
the endometrium, and get nourishment from blood vessels which develop solely for this 
purpose. The fertilized ovum becomes an embryo, which gets attaches to the wall of the 
uterus, creates a placenta, and develops into a fetus until childbirth.  
Clinical significance 
A hysterectomy is the surgical exclusion of the uterus which may be carried out 
for a number of reasons including the eradication of tumors both benign and malignant. 
A complete hysterectomy involves the complete removal of the parts of uterus which 
includes the body, fundus, and cervix of the uterus. A partial hysterectomy may just 
involve the removal of the uterine body while leaving the cervix intact. It is the most 
commonly performed gynecological surgical procedure. 
Some pathological states include: 
 Prolapse of the uterus 
 Carcinoma of the cervix –  known malignant neoplasm 
 Carcinoma of the uterus –  known as malignant neoplasm 
 Fibroids –  known as benign neoplasms 
 Adenomyosis –  which is the ectopic growth of endometrial tissue within the 
myometrium 
 Endometritis– defined as the infection at the uterine cavity. 
 Uterine malformations– congenital malformations which includes uterine 
Didelphys,bicornuate uterus and septate uterus.  
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 Asherman's syndrome– known as intrauterine adhesions  which occurs when the 
basal layer of the endometrium is damaged by infection (e.g. 
endometrial tuberculosis) resulting in endometrial scarring followed by adhesion 
formation which partially or completely obliterates the uterine cavity. 
 Hematometra–accumulation of blood within the uterus. 
 Myometritis – inflammation of the muscular uterine wall. [18] [19] 
 
OXYTOCIN 
Oxytocin is a hormone which is made in the brain, in the hypothalamus. It is 
transported to and secreted by the pituitary gland, which is situated at the base region of 
the brain. Oxytocin is classed as a nonapeptide (a peptide containing nine amino acids) in 
chemistry and in biological classification it is considered as a neuropeptide. It acts both 
as a hormone and also as a brain neurotransmitter. 
The release of oxytocin by the pituitary gland acts to control two female reproductive 
functions: 
 Childbirth 
 Breast-feeding. 
The release of the hormone oxytocin during labor is responsible for increasing the 
uterine motility and making the muscles of the uterus (womb) contract. The release of 
oxytocin is stimulated by the widening of the cervix and vagina during labor and this 
effect is in turn increased by the subsequent contractions. It is released in large amounts 
during the time of labor, and after stimulation of the nipples. It is a facilitator for 
childbirth and breast-feeding. 
Biosynthesis 
The oxytocin peptide is synthesized as an inactive precursor protein from 
the OXT gene. This precursor protein also includes the oxytocin carrier protein which is 
the neurophysinI. The inactive precursor protein is gradually hydrolyzed into smaller 
fragments via a series of enzymes. The last hydrolysis that releases the active oxytocin 
nonapeptide is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM). 
The activity of the PAM enzyme system is dependent upon vitamin C which is an 
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essential vitamin cofactor. By chance, sodium ascorbate by itself was found to motivate 
the production of oxytocin from ovarian tissue over a range of concentrations in a dose-
dependent manner.  
Neural sources 
In the hypothalamus, oxytocin is made in magnocellular neurosecretory cells of 
the supraoptic and paraventricular nuclei, and is stored in Herring bodies at the axon 
terminals in the posterior pituitary. It is then released into the blood from the posterior 
lobe (neurohypophysis) of the pituitary gland. These axons have collaterals that 
innervate neurons in the nucleus accumbens, a brain structure where oxytocin receptors 
are being expressed. The common release of the hormone through these collaterals is 
responsible for the endocrine effects of hormonal oxytocin and the cognitive or 
behavioral effects of oxytocin neuropeptides. Oxytocin is also produced by some 
neurons which is present in the paraventricular nucleus that project to other parts of the 
brain and to the spinal cord.  
In the pituitary gland, oxytocin is packaged in large thick core vesicles, where it 
is bound to neurophysinI. It is a large peptide fragment of the larger 
precursor protein molecule from which oxytocin is derived by the enzymatic cleavage. 
Electrical activity of the oxytocin cells in the hypothalamus regulates the 
secretion of oxytocin from the neurosecretory nerve endings. The action potentials 
generated by these cells   propagate down axons to the nerve endings in the pituitary. 
Oxytocin gets released by the process of exocytosis when the nerve terminals get 
depolarized. 
Non-neural sources 
Endogenous oxytocin concentrations in the brain have been found to be as much 
as 1000 times higher than the peripheral levels. Besides the brain, oxytocin containing 
cells are present in several other tissues, in females in the corpus luteum and the 
placenta, and in males it is in the testes. It is also be present in the retina, the adrenal 
medulla, the thymus and the pancreas.   
Male  
 In some species the Leydig cell have the biosynthetic mechanism to produce 
testicular oxytocin, to be specific, in rats (which can synthesize vitamin C 
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endogenously), and in guinea pigs, which, like humans, require an exogenous source of 
vitamin C in their diets. 
Female 
Oxytocin is synthesized by corpora lutea of several species, including ruminants 
and primates. Along with estrogen, it is involved in triggering the endometrial synthesis 
of prostaglandin F2α which causes regression of the corpus luteum.
[20] 
 
RAT REPRODUCTIVE SYSTEM 
The female reproductive system consists of the two ovaries and the female 
genital tract. The genital tract includes the oviducts, uterus, cervix and vagina. The 
female genital tract in mammals arises from the Mullerian ducts, commencing with the 
ostium of the oviduct. In the rat, this ostium forms a complete capsule called the ovarian 
bursa, which envelop the ovary. The oviducts are small, extremely coiled tubes. The 
uterus consists of two separated uterine horns, which enables the rat to have multiple 
offspring. The vagina of the rat opens directly to the exterior region. 
Estrous cycle    
The rat estrous cycle is short, which is lasting four to five days. It occurs 
throughout the year, without any seasonal effect. The first regular estrous cycle occurs 
about one week after the opening of the vaginal orifice, usually 33 to 42 days after birth. 
The cycle length increases slightly with age and last about 6 days near the ending of the 
reproductive life span. 
The estrous cycle in the rat consists of four stages known as proestrus, estrus, 
metestrus and diestrus. Proestrus lasts approximately 12 h; estrus, 9 to15 h; metestrus, 21 
h; and diestrus (the longest phase), over 57 h.  
Hormones play significant roles in the estrous cycle of the rats. Gonadotrophins, 
which are secreted by the anterior pituitary gland, regulate the estrous cycle through 
luteinizing hormone (LH) and follicle stimulating hormone (FSH). Hormonal 
fluctuations result in ovarian and follicular changes, as well as changes in vaginal 
cytology. FSH stimulates follicle growth, while LH stimulates the follicles to ovulate and 
form the corpus luteum. Progesterone is secreted by the corpus luteum during metestrus 
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and declines during diestrus. During the follicular development, the level of estradiol-
17β increases. The cycle ends when estrogen peaks during proestrus, stimulating 
gonadotropin release to trigger ovulation.  
Identification of estrous cycle stages  
Estrous cycle phases can be noticed by observing behavioral changes or vaginal 
cytology examination. The latter method is widely used and considered as a practical 
way to determine the phases of the estrous cycle. Precise phase identification depends on 
smears taken at fixed times in the day, as the cell populations vary throughout a 24-h 
period. Behavior and vaginal smear morphology during the different phases of estrous 
cycle as well as the duration of each phase are shown in figure 3. Estrus is defined as the 
period when the female accepts the male and allows copulation. Many behavioral 
changes occur during this phase, including increased running activity, lordosis and ear 
quivering. During estrus, dry vaginal wall and a swollen vulva can also be observed. The 
female accepts the male at the end of proestrus, while during metestrus and diestrus, the 
female does not accept the male. Vaginal cytology in estrus reveals cornified cells and 
nucleated cells. In metestrus, leukocytes, nucleated cells and cornified cells are seen. In 
diestrus, which is the longest phase, vaginal cytology principally reveals leukocytes. 
Nucleated cells are predominant in vaginal smears during proestrus. 
 
 
Figure 3: Diagram showing stages of estrus cycle in rats 
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Stages of the Estrous Cycle 
The stages of the estrous cycle are identified by the absence, presence, or 
proportion of the described four basic cell types as well as by the cell density and also 
arrangement of the cells on the slide. The following will define and characterize the 
range in appearance of the four classic stages: 
Proestrus 
Proestrus is a short stage, lasting an average of 14 hr in rats and less than 24 hr in 
mice. The predominant feature of this stage is the presence of small, round, nucleated 
epithelial cells of relatively uniform appearance and size; these cells may stain deeply 
basophilic. Often they will be seen in cohesive clusters, sheets, or strands.  
However, cohesive clusters, sheets, and strands are not always observed, 
especially in low cellularity samples, and should not be thought of as a prerequisite in the 
determination of proestrus; cells may only be seen individually throughout the smear. 
Typically, no neutrophils will be seen.  Rare to occasional neutrophils can be found in 
early proestrus as the rodent would have recently transitioned from diestrus into 
proestrus stage. Relatively less numbers of large epithelial cells and keratinized 
anucleated cells may also be observed. As the cycle approaches estrus, keratinized cells 
will become more abundant. The presence of low numbers of neutrophils, or large and 
anucleated epithelial cells, does not preclude the diagnosis of proestrus when the 
predominating feature of the smear are the small, round epithelial cell population. 
 
Estrus 
 
Estrus duration ranges between 24 and 48 hr in rats and between 12 and 48 hr in 
mice. It is characterized by the presence of predominately anucleated keratinized 
epithelial cells. Numerous bacteria may be observed adhered to the cells or free in the 
background. Occasional nucleated epithelial cells can also be observed throughout the 
stage of estrus, and neutrophils are absent or occasionally observed in late estrus. The 
first and second half of estrus, while consisting mostly of anucleated keratinized cells, 
have distinct differences in their appearances and also differ between rats and mice. The 
second phase in rats occurs late in estrus and will not always. 
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Metestrus 
Metestrus is comparatively a short stage of the estrus cycle which lasts for 6–8 hr 
in rats. This stage is characterized by a combination of keratinized epithelial cells 
(anucleated) and neutrophils. In mice, nucleated cells may appear occasionally 
throughout metestrus.  In rats, the small and large nucleated cells of late estrus are 
present in low to moderate numbers throughout the stage. In early metestrus, neutrophils 
are interspersed with the epithelial cells and are sometimes tightly packed together or 
clumped around the cells; the epithelial cells usually predominate but may be in equal 
proportion to the neutrophils. As metestrus progresses, neutrophils become very high in 
number and the smear will be highly cellular and dense. Neutrophil and epithelial cell 
numbers decrease by late metestrus, with a decrease in smear cellularity, before the 
transition to diestrus.  
Diestrus 
 
Diestrus is the longest stage of the estrus cycle with an average duration of 48–72 
hr in both mice and rats. This stage is characterized by a substantial decrease in the 
number of anucleated keratinized epithelial cells as the animal transitions out of 
metestrus. In general cellularity is moderate to low with a combination of neutrophils, 
small and large nucleated epithelial cells, and low numbers of anucleated keratinized 
cells. Neutrophil numbers can vary but are usually higher in number relative to the 
epithelial cells with smears sometimes being exclusively neutrophilic. Occasionally, in 
early diestrus, neutrophils may still appear in clumps. It is not unusual for diestrus 
smears to have a very low cellularity, especially on day 2 or 3 of diestrus, with only a 
sparse spreading of neutrophils and epithelial cells. In late diestrus, the epithelial cells 
may become more round or be organized in small clumps, indicating proestrus the next 
day. During diestrus, macroscopic vaginal excretions are low. When excreations are 
present, however, they can be viscous and stringy and this is especially true during times 
of persistent diestrus. This excretion is sometimes aspirated during vaginal cytology 
sample collection. It will stain and appear as a thick pink to blue-violet material with 
entrapped neutrophils and epithelial cells. The cells may be distorted or elongated in the 
strings of mucous. [21] [22] 
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OXIDATIVE STRESS 
Oxidative stress is an imbalance between free radical production and antioxidant 
defenses and is associated with damage to a wide range of molecular species including 
lipids, proteins and nucleic acids. Short-term oxidative stress may occur in tissues 
injured by trauma, infection, heat injury, hypertoxia, toxins and excessive exercise. 
These injured tissues produce increased radical generating enzymes (e.g., xanthine 
oxidase, lipogenase, cyclooxygenase) activation of phagocytes, release of iron, copper 
ion or a disruption of the electron transport chains of oxidative phosphorylation 
producing excess ROS. [23] 
Risk factors of PTB and pPROM can be classified into two major categories, 
static and dynamic. Independently or in combination, the static risk factors can either 
predispose or cause the dynamic risk factors that are commonly diagnosed as clinical 
risks. Epigenetic changes that are independent of DNA base variations generated by 
complex interactions between various risk factors during pregnancy can also contribute 
to dynamic clinical risks by altering expression of certain genes. These changes can 
cause transition between static and dynamic risks. Static and dynamic risk factors 
produce pathways and pathophysiologies depicted in the inner circle with a unique 
biomarker profile contributing to labor-inducing changes, resulting in PTB or pPROM. 
The final effector pathways culminating in labor and delivery include inflammation and 
oxidative stress (OS). In normal pregnancies, these are generated by various fetal and 
maternal factors that signal the end of pregnancy. In PTB, the maternal–fetal signals and 
their causal origins are still unclear as they arise from complex etiologies and redundant 
pathways. [24] 
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Figure4: A model of reactive oxygen production, its inactivation by antioxidant 
systems and potential consequences of redox imbalances 
 
 
MATERNAL/FETAL ANTIOXIDANTISSUES 
 
During pregnancy itself there is a burden of excess and unstable radicals on 
maternal tissues as well as those of the developing fetus and placenta. The subsequent in 
ability to vasodilate (or direct vasoconstriction) caused by these reactive species result in 
diminished blood flow and can lead to PTL, PPROM, preeclampsia, and primary IUGR 
(or secondary due to the preeclampsia).Numerous strategies are adopted to address this 
excess of oxidative radicals, particularly supplementation of one or two micronutrients in 
the hopes of reducing these serious maternal/fetal disorders. Such therapy is directed at 
decreasing the numbers of reactive oxygen/nitrogen species by supplementing vitamins 
A, C or E in hope of reducing vasoconstriction and/or organ damage. According to the 
hypothesis if vasoconstriction is reduced there would be less early deliveries both from 
PTL and PPROM as well as from indicated deliveries due to preeclampsia and severe 
fetal growth restriction. 
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ENZYMATICANTIOXIDANTDEFENSES 
 
Antioxidant enzyme activities have been shown to increase in response to 
oxidative stresses. Antioxidant enzymes take part in a complex interaction of reducing 
and oxidizing molecules that defines the cellular milieu necessary for maintaining 
cellular, placental, fetal, postnatal growth. Such enzymes have small activity in preterm 
infants and cannot balance excessive ROS production. The most significant antioxidant 
enzymes are copper-zinc superoxide dismutases (SOD), which are found in cytoplasm as 
well as peroxisomes, and manganese SOD from mitochondria. SOD catalyzes the 
dismutation of superoxide anion to H2O2. Glutathione peroxidase (GPx) in mitochondria 
and catalase (CAT) in peroxisomes catalyze the reaction of H2O2 to molecular oxygen 
and water. These enzymes, together with vitamin E, play an important role in the 
peroxidation of polyunsaturated free fatty acids in cell membrane. [25] 
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2. REVIEW OF LITERATURE 
 
Syama Hari Priya et al., (2017) performed the antioxidant activity, phenolic-flavonoid 
content and high-performance liquid chromatography profiling of three different variants 
of Syzygium cumini seeds: A comparative study. S. cumini is widely used in traditional 
systems of medicines in India, such as Ayurveda, Unani, and Siddha. Different parts of 
S. cumini are reported to have several medicinal properties like antidiabetic, 
antimicrobial, anti-inflammatory and free radical scavenging potential. The seeds have 
been reported to possess compounds such as jambosine, gallic acid (GA), ellagic acid, 
corilagin, 3,6-hexahydroxy diphenoylglucose, 1-galloylglucose, 3-galloylglucose, 
quercetin, β-sitoterol and 4,6 hexahydroxydiphenoylglucose . The phenolic profiling of 
active fractions of all the variants indicated the presence of prominent phenolic 
compounds which were known for their antioxidant potential. [26] 
 
Kuldip Singh et al., (2016) studied the antioxidant and antimicrobial potential of 
Syzygium cumini leaves and found that high contents of phenol present in different 
extracts of Syzygium cumini leaves. The presence of high contents of phenol suggested 
the antioxidant properties to scavenging the production of ROS and lipid peroxidation. 
Antimicrobial activity of the various leaves extract was checked by Agar Well Diffusion 
and Micro Dilution Broth method. Antimicrobial activity was tested by four bacteria 
(Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa and Staphylococcus 
aureus) and two fungus (Aspergillus niger and Trichoderma viridae). The outcome 
showed that the activity of various leaves extracts of Syzygium cumini shows significant 
antibacterial and antifungal activities. These antimicrobial activities of extracts may be 
due to presence of different phytochemicals. [27] 
 
Madhulika Pradhan (2016) studied phytochemistry, pharmacology and novel delivery 
applications of Syzygium cumini (L.). S.C is a widely used medicinal plant for the 
treatment of various ailments. The plant contains anthocyanins, glucoside, ellagic acid, 
isoquercetin, kaempferol, and myricetin as its chief active constituents. These active ions  
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isoquercetin, kaempferol impart multiple pharmacological activities to the plant which 
includes antidiabetic, anticancer, antioxidant, antibacterial, antifungal and antidiarrhoeal 
activity.  [28] 
 
Deepali Laxman Jaybhaye et al., (2016) studied tocolytic plant Tectona grandis Linn. 
extended study on other systemic effect. Tectona grandis Linn. (T.G) is one of the well-
known Indian herbs. In Ayurveda, T.G stem extract has tocolytic effect. Conventional 
tocolytic drugs are known to have cardiovascular, skeletal muscle toxicity. This study is 
undertaken to observe possible adverse effects of T.G stem extract especially on 
cardiovascular and musculoskeletal system. After analysis by t‑test, it was observed that 
T.G causes vasodilatation same as that of the sodium nitrate, without causing any cardiac 
toxicity seen with nifedipine and no neuromuscular blockade as seen with magnesium 
sulfate.  [29] 
 
Shweta Sharma et al., (2016) performed comparative study of alcoholic and aqueous 
extracts of syzygium cuimini on carbon tetrachloride-induced hepatotoxicity in wistar 
rats.  Hepatotoxicity means chemical-driven liver damage since liver cells are main site 
of detoxification and drug metabolism, certain toxin/ drug might injure the organ. 
Hepatic injury was induced by single oral administration of CCl4 mixed with olive oil as 
vehicle in 1:1 ratio (3 ml/kg of rat body weight). In this experiment, it was found that the 
aqueous extract has more hepatoprotective activity than alcoholic extract of Syzygium 
cumini. In addition, their protective efficacy was also found to be comparable to that of 
standard drug used. [12] 
 
Sekar et al., (2015) evaluated hepatotoxic effect of ethanolic extract of Syzygium cumini. 
Linn leaves on experimental animals. Ethanolic extract of Syzygium cumini have been 
reported to possess significant anti-inflammatory, diuretic, anti-hyperglycemic, 
hepatoprotective, chemopreventive and anti-diabetic. The present study reports 
hepatotoxicity of ethanolic extract of Syzygium cumini leaves on experimental rats at 
dose levels of 1250, 2500 and 5000mg/kg body weight for 28 days. The extract has 
reduced glucose levels considerably but the levels of body weights, RBC, WBC, 
Hemoglobin, AST and ALT were found to be elevated. [6] 
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Michelle C. Cora et al., (2015) evaluated vaginal cytology of the laboratory rat and 
mouse:review and criteria for the staging of the estrous cycle using stained vaginal 
smears. The estrous cycle is generally divided into the four stages of proestrus, estrus, 
metestrus, and diestrus. On cytological evaluation, these stages are defined by the 
absence, presence, or proportion of 4 basic cell types as well as by the cell density and 
arrangement of the cells on the slide. Vaginal cytology can be evaluated immediately 
after collection as an unstained, wet mount preparation (direct cytology) or as a fixed and 
stained slide preparation. [17] 
 
Swadhin Ranjan Behera et al., (2014) studied the hepatoprotective activity of aqueous 
extract of Syzygium cumini seed on streptozotocin induced diabetes in rats. It was 
observed that aqueous seed extract of S.C (500mg/kg) showed significant 
hepatoprotective effect in diabetic rats compared to other groups. The present protective 
effect may be due to saponins, tannins and flavanoids present in seed extract. Standard 
oral hypoglycemic drug and high dose of seed extract showed almost normal levels of 
liver enzymes. But 250mg/kg do not show significant effect compared to standard and 
high dose plant extract administered groups. It indicates that low doses plant extract do 
not show hepatoprotection. This may be due to antioxidant property of seed extract. 
Antioxidants counteract the oxidants generated in the liver. Any changes between levels 
of oxidants and antioxidants cause development of   liver damage. [30] 
 
Ramkumar Menon (2014) studied oxidative stress damage as a detrimental factor in 
preterm birth pathology.  Normal term and spontaneous preterm births (PTB) are 
documented to be associated with oxidative stress (OS) and imbalances in the redox 
system.  A healthy pregnancy is characterized by a stable balance between ROS and 
antioxidants. Redox imbalance is an under- lying pathologic feature of many pregnancy 
complications. All of the PTB and pROM risk factors detailed above are capable of 
causing redox imbalance, leading to the production of superoxide, hydrogen peroxide, 
hydroxyl ions, and nitric oxide that can damage collagen matrix and consume antioxidant 
defenses. These events can trigger uterine contractions (labor), leading to PTB. [24] 
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Swadhin Ranjan Behera et al., (2014) studied nephroprotective effect of aqueous 
extract of Syzygium cumini seed on streptozotocin induced diabetes in rats. 30 rats were 
divided into 5 groups. G-I (Control) normal saline was administered. 24 rats were 
administered streptozotocin to induce diabetes. After 72hr blood glucose was measured. 
G-II-diabetic control, G-III- Streptozotocin (45mg/kg/i.p/0day) + Glibenclamide 
(5mg/kg/orally/120days), G-IV-Streptozotocin (45mg/kg/i.p/0day) + Aqueous extract of 
Syzygium cumini seeds (250mg/kg/orally/120 days) and G-V- Streptozotocin 
(45mg/kg/i.p/0day)+ Aqueous extract of Syzygium cumini seeds 
(500mg/kg/orally/120days). It was observed that aqueous extract of S.C seed extract 
showed significant nephroprotective effect compared to other groups. This seed powder 
extract can use to treat patients having kidney problems along with diabetes. [31] 
 
Katherine Y Bezold  et al., (2013) observed the genomics of preterm birth: from animal 
models to human studies. The use of animal models to study the events leading up to and 
throughout birth has provided significant insight into the mechanisms regulating 
parturition, at term and preterm. However, the applicability of current animal models of 
parturition to the physiological mechanisms of human pregnancy and birth has been 
limited, as the means by which these different species regulate and initiate parturition 
differ from each other and from humans. [32] 
 
Naguib Salleh et al., (2013) observed the In-Vitro effect of Ficus deltoidea on the 
contraction of isolated rat’s uteri is mediated via multiple receptors binding and is 
dependent on extracellular calcium. Ficus deltoidea, is a perennial herb that is used to 
assist labor, firm the uterus post-delivery and to prevent postpartum bleeding. FDA-
induced contraction of the isolated rat’s uteri is mediated via multiple uterotonin 
receptors (muscarinic, oxytocin and prostaglandin F2α) and was dependent on the 
extracellular Ca2+. Contraction, however, was not dependent on the Ca2+ release from 
the internal stores. This in-vitro study provides the first scientific evidence on the 
claimed effect of Ficus Deltoidea on uterine contraction. [33] 
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Huda Yahia Hamid et al., (2013) studied reproductive characteristics of the female 
laboratory rat. The estrous cycle consists of four stages known as proestrus, estrus, 
metestrus and diestrus. Phases of the estrous cycle can be detected by observing 
behavioral changes or examining vaginal cytology.  Detection of sperm in vaginal smear 
is an excellent predictor of pregnancy in rats. Implantation is initiated on day 5 and 
completed by day 7 of pregnancy. Gestation takes 21 to 23 days from copulation to 
parturition. Short estrous cycle and gestation period make the rat an ideal animal model 
for research on reproduction. On the other hand, detection of sperm in vaginal smear is 
an excellent predictor of pregnancy in rats. The day that sperm is detected in the vaginal 
smear is designated as day 1 of gestation. [34] 
 
Lekha K Nair et al., (2013) studied the invitro antioxidant activity of the seed and leaf 
extracts of Syzygium cumini. The extract showed significant antioxidant activity in all 
antioxidant assays when compared to ascorbic acid. The results of this research work are 
promising thus indicating the utilization of the seed and leaf of Syzygium cumini as a 
significant source of natural antioxidants. [35] 
 
Asiqur  Rahaman et al., (2013) evaluated the  memory  related  learning ability of old 
rats in eight arm radial maze  using Syzygium cumini (L.) Seed extract .The study 
demonstrated that the oral administration of S. cumini seed extract improves radial arm 
performance in old rats concomitantly with the amelioration of the levels of LPO in the 
cerebral cortex and hippocampus. Radial maze behavior allows the simultaneous 
measurement of reference memory and working memory without any harmful effects on 
the rats. [36] 
 
Bhaskar Sharma et al., (2013) studied Liver protective effects of aqueous extract 
of Syzygium cumini in Swiss albino mice on alloxan induced diabetes mellitus. Eighteen 
Swiss albino mice (weighing 28–32 g) were randomly divided into control, alloxan 
treated and S. cumini treated mice group. Diabetes was induced in mice by injecting 
intraperitoneally alloxan monohydrate at dose of 150 mg/kg body weight. Aqueous 
extracts of S. cumini seed at dose of 250 mg/kg body weight were given orally in diabetic  
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mice daily for three weeks after established LD50 value. In diabetic mice, the SGOT, 
SGPT, Bilirubin and serum glucose levels were significantly increased in comparison 
with the control groups. Statistical analysis (p < 0.05) of the data indicated that aqueous 
extract of S. cumini were significantly decrease serum contents of liver enzymes (SGOT, 
SGPT and Bilirubin) as well as serum glucose in treated groups. [37] 
 
Md. Rashedul  Alam  et al., (2012)  studied  the  antidiabetic phytochemicals in 
Syzygium cumini(L.) skeels. The present study was carried out to identify the putative 
antidiabetic constituents from the S. cumini leaves. From the NMR data four different 
compounds, Lupeol, 12-oleanen-3-ol-3ß-acetate, Stigmasterol, ß- sitosterol were 
identified from n-hexane fraction of plant extract. These compounds have potential 
antidiabetic activities which support the traditional use of the leaves as being remedy for 
treating diabetes. [38] 
 
Shweta sharma et al., (2012) evaluated the pharmacological activity of Syzygium cumini 
extract using different solvent and their effective doses. In this review it is concluded that 
the plant having potential of treating various highly dangerous disease which are 
responsible for mortality in different age group. S.C reduces the radiation induced DNA 
damage in the cultered human peripheral blood lymphocytes in preliminary level study 
in the dose of 100µg/ml. Plant extracts have been examined for their antidiabetic 
properties in an effort to identify alternative treatment strategies pose less of a risk for 
diabetes. S.C ameliorates insulin resistance and β-cell dysfunction via modulation of 
PPARγ, dyslipidemia, oxidative stress and TNF-α in type 2 diabetic rats. S.C skeels are 
effective on post prandial blood glucose levels in non diabetic rats and rats with 
streptozocin –induced diabetic mellitus. [39]  
 
Robert A. Knuppel et al., (2012) studied oxidative stress and antioxidants: preterm birth 
and preterm infants. It was found that the oxidative stress during pregnancy yields free 
radicals and other oxidative molecules exceeding the available antioxidant buffering 
capacity in the mother and growing fetus. This results in cellular damage, which is 
associated not only with PTL and delivery, but also preeclampsia, PPROM and IUGR as  
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well as several serious post delivery issues for the premature infant. Antioxidant 
enzymes participate in a complex interaction of reducing and oxidizing molecules that 
defines the cellular milieu necessary for maintaining cellular, placental, fetal, and 
postnatal growth. Such enzymes have low activity in preterm infants and cannot balance 
excessive ROS production. The most important antioxidant enzymes are copper-zinc 
superoxide dismutases (SOD), which are found in cytoplasm as well as peroxisomes, and 
manganese SOD from mitochondria. [25] 
 
Yavuz Simsek et al., (2012) studied elevated cardiac oxidative stress in newborn rats 
from mothers treated with atosiban. The animals were treated from days 15 to 20 of 
gestation. One group acted as a control group, and received intraperitoneal (i.p.) 
injections of saline in a daily dose volume of 6 mg/kg/day. The second group received 
6 mg/kg/day i.p. atosiban. There was no significant difference in birth weight or in the 
number of pups between two groups. Newborns from atosiban-treated mothers showed 
significantly increased oxidative stress in the plasma and heart tissue than that of 
controls. [40] 
 
Prashant B. Shamkuwar et al., (2012) evaluated the antidiarrhoeal activity of seeds of 
Syzygium cumini L. Aqueous Syzygium cumini extract (125, 250, 500 mg/kg, po) was 
tested for its antidiarrhoeal, antimotility and antisecretory activity in mice. The method 
of castor oil induced diarrhoea was used to evaluate antidiarrhoeal activity; while 
charcoal meal test and castor oil induced intestinal secretions were used for testing 
antimotility and antisecretory activity in mice. Aqueous Syzygium cumini extract (ASC) 
produced a significant and dose dependent antidiarrhoeal,antimotility, and  antisecretory 
effect. It can be concluded that ASC possesses antidiarrhoeal effect may be due to its 
antimotility and antisecretory effect. [41] 
 
C. Hubinont et al., (2011) evaluated prevention of preterm labour: 2011 update on 
tocolysis. Preterm delivery is defined by a birth occurring before 37 weeks of gestation 
or before 259 days from the last menstrual period. Tocolytic therapy includes β 
adrenergic receptor agonists, NO donors, magnesium sulphate, prostaglandin-synthase 
inhibitors, oxytocin receptor antagonists, calcium channel blockers, progesterone, 17-α- 
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hydroxyprogesterone caproate, and antibiotics. Atosiban, an oxytocin receptor antagonist 
and prostaglandin-synthetase inhibitors have uterine relaxation effect by interfering with 
endogenous myometrial stimulators. The only drug used in clinical practice is atosiban. 
It blocks in a reversive manner the intra cytoplasmic calcium release associated with 
contractions and downregulates prostaglandin synthesis. [7] 
 
Nikolaos Vrachnis et al., (2011) evaluated the oxytocin-oxytocin receptor system and 
its antagonists as tocolytic agents. Oxytocin, a hormone involved in numerous 
physiological processes, plays a central role in the mechanisms of parturition and 
lactation. It acts through its receptor, which belongs to the G-protein-coupled receptor 
super family, while Gq/phospholipaseC (PLC)/inositol 1, 4, 5-triphosphate (InsP3) is the 
main pathway via which it exerts its action in the myometrium. Oxytocin receptor 
antagonist that blocks OT binding to OTR and is the only oxytocin antagonist used today 
for the treatment of preterm labor. [42] 
 
Christine K. Ratajczak et al., (2010) evaluated preventing preterm birth: the past 
limitations and new potential of animal models. The use of humans in controlled studies 
on parturition is severely limited by ethical considerations. However, studies of other 
animals, notably sheep and mice, have made key contributions to the understanding of 
parturition. The use of each of these model systems has its own advantages and 
disadvantages. Although animal models are not without their limitations in modeling 
human parturition biology, they have made important contributions to our current 
understanding of this complex process. Differences in how parturition is executed in 
common animal models and humans have been identified, but these differences should 
not discourage investigators from conducting further research to identify additional 
important similarities. [43] 
 
Omonkhelin j. owolabia et al., (2009) evaluated the tocolytic activity of ethanol extract 
of the stem bark of ficus capensis thunb. (moraceae). The ethanolic extract obtained by 
maceration technique was subjected to pharmacological testing in vitro on a piece of 
isolated rat uterus previously pretreated with stilbestrol, suspended in De Jalon at 37OC.  
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The higher concentration of the extract (80 mg/mL) significantly (p < 0.05) exerted 
smooth muscle relaxant activity on the uterus. The results indicate the presence of active 
principles in the bark extract of Ficus capensis which may be responsible for some of the 
applications in traditional medicines as an anti-abortifacient and as a remedy against 
threatened abortion. [44] 
 
A. Kumar et al., (2008) studied anti-inflammatory activity of Syzygium cumini seed. 
This study was intended to evaluate the anti-inflammatory activity of ethyl acetate and 
methanol extracts of S. cumini seed in carrageenan induced paw oedema in wistar rats at 
the dose level of 200 and 400 mg/kg administrated orally. Both the extracts exhibited 
significant anti-inflammatory activity, which supports the traditional medicinal 
utilization of the plant. [45] 
 
P. Suresh Kumar et al., (2006) studied the in vitro tocolytic activity of Sarcostemma 
brevistigma Wight. The effect of a chloroform soluble fraction (F-A)  of the acetone 
extract of twigs of Sarcostemma brevistigma Wight on contractions induced by oxytocin 
and KCl, in the isolated rat uterine smooth muscles, has been evaluated. At 
concentrations of 32.8 μg/ml, the F-A significantly inhibited (P<0.001) the contractions 
induced by 60 mM KCl in Ca
2+
, containing physiological salt solution to the extent of 
88.7 ± 2.2%. The F-A, at concentrations of 26.3 μg/ ml, completely inhibited the 
rhythmic contractions induced by oxytocin in Ca
2+
, containing physiological salt 
solution. However, it failed to inhibit the contractions induced by oxytocin in Ca
2+ 
free 
PSS. These results suggest that fraction F-A exhibits uterine relaxant activity, by 
interfering with the extracellular Ca
2+. [46] 
 
Ochiogu et al., (2006) performed a new and simple method of confirmatory detection of 
mating in albino rats (Rattus norvegicus). The method involved the gross observation of 
grey to yellowsh protein coagulates (remnants of the copulatory plug) on vaginal smears 
of mated females made on clean glass slides. The copulatory plug, also known as the 
vaginal plug, is a white or grey to yellowish waxy coagulated mass of proteins which is  
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usually deposited by males in the female reproductive tract at mating in some 
mammalian species including rats. This new method is simple, easy to apply and does 
not interfere with fertilization and pregnancy, and also does not involve either the use of 
specially designed rat cages or microscopy of vaginal smears, which were the constraints 
of the former methods of confirming mating in rats. [47] 
 
Ronald F. Lamont (2003) studied the development and introduction of anti-oxytocic 
tocolytics. The perfect tocolytic agent, which is completely safe for both the mother and 
fetus and, which will inhibit uterine contractions and stop preterm labour in every case 
does not exist and the search continues. The analogue, atosiban, was found to be more 
potent and so was chosen for clinical evaluation in dysmenorrhoea and preterm labour. 
Atosiban was found to be at least as effective as the beta agonists as a tocolytic agent, 
but significantly less likely to result in maternal cardiovascular side effects or the need to 
discontinue therapy as a result of unacceptable side effects. [48] 
 
Masatoshi Sakai et al., (2001) evaluated the tocolytic effect of a selective 
cyclooxygenase -2 inhibitor in a mouse model of lipopolysaccharide induced preterm 
delivery. The inflammatory process is known to cause preterm birth. In this study the 
COX-2 inhibitor celecoxib was studied for its tocolytic effect and its side effect on 
dams and pups using a lipopolysaccharide (LPS)-induced preterm delivery mouse 
model. With administration of 10 or 100mg/kg celecoxib the fetal ductus arteriosus 
was constricted significantly in preterm and near term rats, although constriction 
rates preterm rats were significantly lower than those in near-term rats. Reproductive 
and renal functions in offspring whose mothers where treated with LPS and celecoxib 
were normal. These data demonstrate that celecoxib can be used as new therapy for 
preterm labour. [49] 
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3. PLANT PROFILE 
                                        
Figure 5:  S. cumuni (seed) 
3.1 Description of the plant: [50, 51, 52] 
Botanical name  : Syzygium cumini 
Family              : Myrtaceae 
Genus               : Syzygium 
Species   : S. cumini 
Synonyms   : Calyptranthes caryophyllifolia Wild. 
3.2 Vernacular name:  
Spanish         : Ciruleo de Java 
Portuguese    : jamelao 
French    : Jambolanier 
Hindi     : Jamun 
Tamil               : Naval 
Malayalam     : Njaval 
 
 
 
                                                                                                    Plant Profile 
 
Department of Pharmacology                                                                              Page 33                                                               
 
 
3.3 Species and distribution 
This species is distributed in tropical and subtropical Asia to Queensland. It is thought to 
be indigenous to India, Myanmar, Sri Lanka and the Andaman islands. It was introduced 
long time ago to Malaysia, Indonesia and the Philippines and has become naturalized. 
 3.4 Plant parts used: 
All parts of the plants are used medicinally especially leaves, seed, stem bark 
3.5 Morphological Characters 
 S. cumini may reach 30 m tall in India and Oceania or up to 12-15 m in Florida, USA, 
with a wide crown up to 11 m in diameter and a trunk diameter of 0.6-0.9 m though it 
usually has a multi-stemmed form branching close to the ground. Bark is rough, 
fractured, flaking and discoloured on the lower part of the trunk, becoming smooth and 
light-grey higher up. Evergreen leaves have a turpentine smell, and are opposite; pinkish 
when young, becoming leathery, glossy, dark-green above, lighter beneath, with a 
conspicuous, yellowish midrib when grown-up. Flowers are fragrant and appear in 
clusters, white at first, becoming rose-pink, detaching rapidly to leave only the numerous 
stamens. Fruit appear in clusters of just a few or 10-40, are round or oblong. The skin is 
thin, smooth, glossy, and adherent. The pulp is purple or white, very juicy, and normally 
encloses a single, oblong, green or brown seed, up to 4 cm long, though some fruits have 
2-5 seeds tightly dense within a leathery coat, and some are seedless. 
3.6 Chemical constituents in leaf: 
The plant leaves contain an essential oil with pleasing odour. The oil contains terpenes, 
1-limonene and dipentene (20%), sesquiterpenes of cadalane type (40%), and 
sesquiterpenes of azulene type (10% or less). Yield and physical uniqueness of the oil 
varies according to the season of collection. This essential oil is reported to be 
responsible for the antibacterial activity of the leaves. 
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3.7 Chemical constituents in seed: 
The plant seeds are rich in protein and calcium. The seeds enclose tannins (19%), ellagic 
acid, gallic acid (1-2%). A glycoside- Jamboline, starch, Myricyl alcohol in the 
unsaponified fraction of seeds and a small quantity (0.05%) of pale yellow essential oil 
(specific gravity20: 0.926, [α] D- 5.42o) are also present.This constituents may be 
responsible for the hypolipidaemic, hypoglycemic and antianemic effect.  
 
3.8 Chemical constituents in stem bark: 
Stem bark contains pentacyclic triterpenoid betulinic acid (m.p. 306-310oC). Betulinic 
acid is a naturally occurring triterpenoid, which has demonstrated selective cytotoxicity 
against a number of specific tumors and active against a variety of infectious agent like 
HIV, malaria, immunomodulatory and inflammation. 
 
3.9 Traditional Uses 
The bark of the plant has various properties like astringent, refrigerant, carminative, 
diuretic, digestive, antihelminthic, febrifuge, constipating, stomachic and antibacterial 
activity. The fruits and seeds are used to treat diabetes, pharyngitis, spleenopathy, 
urethrorrhea and ringworm infection. The leaves are antibacterial and used to make 
stronger the teeth and gums. The leaves have also been widely used to treat diabetes, 
constipation, leucorrhoea, stomachalgia, fever, gastropathy, strangury, dermopathy and 
to inhibit blood discharge in the feces. The barks, leaves and seeds extracts of S. Cumini 
have also been reported to possess anti- inflammatory, antibacterial and antidiarraheal 
property. Powdered seeds are used as a remedy in diabetes and in menorrhagia.  It has 
been also showed before that the leaf, bark, stem and pulp of S. cumini plants possess 
potent antidiabetic activity 
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4. AIM AND OBJECTIVES 
 
4. 1. AIM: 
Syzygium cumini L. family Myrtaceae is a well-known common fruit in India. 
The seed is used in various alternative healing systems like Ayurveda, Unani and 
Chinese medicine for digestive ailments. The literature study done so far revealed that 
there is a lack of scientific data concerning the tocolytic evaluation of the S.cumini seed 
extract on animal models.  
The aim of the current study is to assess the tocolytic effect of the aqueous seed 
extract of Syzygium cumini on oxytocin induced preterm labour. 
4. 2. OBJECTIVES: 
The objectives of the present study include: 
  Evaluation of in- vitro antioxidant activity of the S.cumini seed extract. 
 Tocolytic activity of S.cumini seed extract. 
 Evaluation of in -vivo antioxidant activity of the S.cumini seed extract 
  Studies on isolated rat uterus 
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5. PLAN OF WORK 
 
The present study examines the efficacy of aqueous seed extract of Syzygium cumini as a 
tocolytic agent. The effect of the drug was evaluated on female wistar rats. 
1. Review of Literatures. 
2. Selection, collection and authentication of plant material. 
3. Extraction of dried seeds with water. 
4. Preliminary phytochemical analysis. 
5. Quantification of total phenol and flavonoid content.  
6. In-vitro antioxidant study. 
 DPPH radical scavenging assay 
 ABTS radical cation scavenging assay 
7. Tocolytic activity 
8. In-vivo antioxidant study. 
 Enzymatic antioxidants(SOD,CAT) 
 Non-enzymatic antioxidant(GSH)  
 Estimation of Lipid Peroxidation (LPO) 
 9. Study on isolated rat uterus tissue 
10. Statistical analysis of the results. 
11. Discussion 
12. Conclusion 
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6. MATERIALS AND METHODS 
6.1 MATERIALS USED FOR THE STUDY 
Table 1: List of instruments 
Sl. No Instruments Manufacturer 
1. Analytical weighing balance Shimadzu 
2. Cooling centrifuge Remi 
3. UV spectrometer Pharmaspec UV-1700, Shimadzu 
4. Kymograph INCO instruments and chemicals  
PVT.LTD 
5. Rotary evaporator IKA  RV 10 
6. Microscope Dollar US -4 
 
 
Table 2: Requirements of the study 
 
DRUGS CHEMICALS OTHERS 
 
1.Oxytocin (Pfizer Ltd) 
2.Atosiban(Emcure 
pharmaceuticals Ltd) 
3.Estradiol valerate (Akums 
Drugs and Pharmaceuticals 
Ltd) 
1.ABTS 
2. DPPH 
3.Phosphate Buffer 
4.Quercetin 
5. Potassium Persulfate 
6.Potassium Ferricyanide 
7.Ferric Chloride 
8.Gallic Acid 
9.Sodium Carbonate 
10.Folin Ciocalteau Reagent 
 
1.Distilled water 
2.Sterile water for injection 
3.Normal saline 
4.Syringe 
5.Needle 
6.Gloves 
7.Droppers 
8.Microscopical slides 
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6.2 PHARMACOGNOSTIC STUDIES 
6.2.1 Collection of Plant material and authentication 
The plant material was collected and authenticated by Dr. K. Madhava Chetty. Ph. D., 
Assistant Professor, Department of Botany, Sri Venkateswara University, Tirupati, 
Andhra Pradesh. The seeds were processed, powdered coarsely and coarse seeds were 
used for extraction 
6.2.2 Extraction of the seeds [41] 
The dried seeds were coarsely powdered. The powdered seeds (200 gm) were taken in a 
round bottom flask and were extracted with water for 48 hr at room temperature. After 
48 hrs, the solution was filtered and the extract was concentrated in a rotary evaporator. 
6.2.3 Preliminary Phytochemical Analysis of the Extract 
The information about the constituents present in the plant clarifies the medicinal uses of 
the plant. Identification and evaluation of herbal extracts is a fundamental procedure and 
parts of quality control protocol. The aqueous extract of Syzygium cumini seed was 
subjected to phytochemical evaluation and identified the various plant constituents 
present in the test samples by qualitatively and quantitatively. The following studies 
were carried out in phytochemical analysis. 
 Qualitative chemical test 
 Estimation of total phenol  
 Estimation of total  flavanoid 
 
6.2.3.1 Qualitative chemical tests [53] [54] [55] [56] 
The qualitative chemical tests were carried out for the extract and identified the various 
secondary metabolites present in the aqueous extract of Syzygium cumini seed.  
Preparation of test sample 
500 mg of the extract was dissolved in 5ml of distilled water and then filtered. The 
filtrate was tested to detect the presence of various phytochemical constituents in the 
sample. 
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TEST FOR CARBOHYDRATES 
 Molisch’s test 
A few drops of Molisch’s reagent were added to 2-3ml of filtrate, and concentrated 
sulphuric acid was added along the sides of the test tube. Violet colour ring formed at the 
junction of two liquids indicates the presence of carbohydrates. 
 Fehling’s test  
Equal volume of Fehling’s- A [copper sulphate in distilled water] and Fehling’s- B 
[potassium tartarate and sodium hydroxide in distilled water] reagents were mixed in a 
test tube and boiled for one minute. 1ml of sample was added to the above mixture and 
heated for few minutes. Brick red precipitate formed confirms the presence of sugars. 
 Benedict’s test  
The test sample was mixed with equal volume of Benedict's reagent (alkaline solution 
containing cupric citrate complex) in a test tube and heated for few minutes. Formation 
of brick red precipitate confirms the presence of sugars. 
 TEST FOR ALKALOIDS 
Small amount of extract was mixed with few ml of dilute hydrochloric acid and filtered. 
The following tests were performed with the filtrate: 
 Dragendorff’s test  
Few drops of the Dragendorff’s reagent (Sodium iodide, basic bismuth carbonate, glacial 
acetic acid and ethyl acetate) were added to 2-3ml of filtrate. Development of orange 
brown precipitate indicates the presence of alkaloids.  
 Mayer’s test  
The filtrate was treated with few drops of Mayer's reagent (mercuric chloride and 
potassium iodide). Formation of yellowish buff coloured precipitate indicates the 
presence of alkaloids.  
 Wagner’s test  
A few drops of filtrate were treated with Wagner's reagent (solution of iodine in 
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potassium iodide) and a reddish brown precipitate obtains to indicate the presence of 
alkaloids. 
 Hager’s test 
A few drops of Hager’s reagent were added to 2-3 mlof filtrate. Development of yellow 
precipitate indicates the presence of alkaloids. 
TEST FOR TRITERPENOID 
 Libermann-Burchard test 
 A small quantity of extract was treated with few drops of acetic anhydride, followed by 
a few drops of concentrated sulphuric acid. A brown ring was formed at the junction of 
two layers and the upper layer turns green colour, infers the presence of phytosterols and 
formation of deep red colour indicates the presence of triterpenoids. 
 Salkowski test 
 A small quantity of the extract was treated with chloroform and a few drops of 
concentrated sulphuric acid and allowed to stand for few minutes. Yellow colour at the 
lower layer indicates the presence of triterpenoids. 
 TEST FOR GLYCOSIDES 
 Legal’s test  
2ml of extract was dissolved in pyridine. Sodium nitroprusside solution was added to it 
and made alkaline. Pink red colour formed indicates the presence of glycosides.  
 Keller-Killiani test 
2ml of extract was dissolved in acetic acid containing trace of ferric chloride and 
transferred to the surface of concentrated sulphuric acid. At the junction of two liquids, a 
reddish brown color formed, which gradually became blue colour due to the presence of 
glycosides. ß Baljet test 2ml of extract was added to sodium picrate solution. Yellow to 
orange colour was formed indicating the presence of glycosides. 
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 TEST FOR STEROIDS AND STEROLS 
 Liebermann- Burchard reaction  
The test sample was dissolved in 2ml of chloroform in a dry test tube. Few drops of 
acetic anhydride were added followed by 2 drops of concentrated sulphuric acid. The 
solution becomes red, then blue and finally bluish green in colour. 
 Salkowski reaction 
 Extract was dissolved in chloroform and concentrated sulphuric acid was added to it. 
Bluish red, cherry red and purple colour was noted in chloroform layer, whereas acid 
layer was marked with green fluorescence. 
 TEST FOR TANNINS 
 Lead acetate test 
1ml of alcoholic solution of extract was diluted with 5ml of distilled water and to this 
few drops of 1% aqueous solution of lead acetate was added. A yellow colour precipitate 
was formed which indicates the presence of phenols. 
TEST FOR SAPONINS 
 Foam Test 
 About 1ml of test sample was diluted separately with distilled water to 20ml and shaken 
in a graduated cylinder for 3 minutes. Foam of 1cm after 10minutes indicates the 
presence of saponins.  
 Froth test  
A drop of sodium bicarbonate was added to 5ml of the test sample. The mixture was 
shaken vigorously and kept for 3minutes. A honey comb like froth was formed which 
shows the presence of saponins. 
TEST FOR PHENOLS 
 Ferric chloride test 
 1ml of the alcoholic solution of the extract mixed with 2ml of distilled water followed 
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by few drops of 10% ferric chloride. Formation of blue or green colour indicates the 
presence of phenols. ß Lead acetate test 1ml of alcoholic solution of extract was diluted 
with 5ml of distilled water and, few drops of 1% aqueous solution of lead acetate was 
added. A yellow colour precipitate was formed which indicates the presence of phenols. 
 TEST FOR FLAVONOIDS  
 Alkaline reagent test 
 A few drops of sodium hydroxide solution was added to the extract. Intense yellow 
colour turned to colourless on addition of few drops of dilute hydrochloric acid, indicates 
the presence of flavonoids.  
 Shinodas test [Magnesium hydrochloride reduction test]  
A small piece of magnesium ribbon and few drops of concentrated HCl were added to 
the alcoholic solution of extract and heated. Appearance of crimson red or occasionally 
green to blue colour infers the presence of flavonoid. 
TEST FOR PROTEINS AND AMINO ACIDS 
 Biuret test  
1ml of test sample was mixed with 1ml of 40 % sodium hydroxide and 2 drops of 1% 
copper sulphate. Formation of violet colour indicates the presence of proteins. 
 Ninhydrin test  
1ml of test sample heated with 2 drops of freshly prepared 0.2% Ninhydrin reagent. 
Development of blue colour indicates the presence of proteins, peptides or amino acids. 
6.2.3.2 Estimation of total phenol content [57] 
The determinations of total phenol content of the extracts were done by Folin-Ciocalteu 
(F-C) assay with some modifications. The Folin–Ciocalteu reagent produces blue colour 
complex when reacted with polyphenol compounds if present in the sample. The assay 
relies on the transfer of reducing electrons in the alkaline medium, from phenolic 
compounds to phospho-molybdic acid complexes, manifested in the formation of blue 
colour that are estimated by UV-visible spectrophotometer (Thermo Fischer model 
Evolution 201). 
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 100 μL sample was taken in 2ml centrifuge tube followed by 0.5ml F-C reagents 
(1:10diluted with distilled water) was added and allowed to react for 5 min before adding 
0.4ml 20% Na2CO3.The above solutions were mixed and allowed to stand 15 min at 
room temperature then measured absorbance of sample at 765nm.The blank was 
prepared in similar manner without sample and standard. Calibration curve was plotted 
using Gallic acid as standard (10, 20, 40, 60, 80,100μg/ml).The results were expressed as 
milligram of Gallic acid equivalents (GAE) per gram of extract. 
6.2.3.3 Estimation of total flavanoid content [57] 
Total flavanoid content was estimated for all the extracts by Aluminium chloride 
colorimetric assay with some modifications. 100μL aliquot of appropriately diluted 
sample or standard solution of quercetin (10, 20, 40, 60, 80 and 100μg/ml) was mixed 
with 50μL of NaNO2 in 2ml micro centrifuge tube. After 6 min, 50μL of a 10% 
aluminium chloride solution was added and allowed to stand for 6 min, and then 50μl 
1M potassium acetate solution was added to the mixture. The final volume was made up 
with distilled water to 2ml, and then the mixture was thoroughly mixed and allowed to 
stand for another 15 min. Absorbance of the mixture was determined at 510 nm against 
prepared blank. Blank was prepared in the same above manner omitting sample and 
standard. All values were expressed as milligrams of quercetin equivalent per 1g of 
sample. 
6.3 IN VITRO ANTI-OXIDANT STUDY 
Various methods are used to investigate the antioxidant property of samples. In the 
present study the antioxidant properties of the extract was evaluated by in vitro methods. 
The antioxidant properties could not be concluded based on the single antioxidant test 
method. It is in practice that generally several in vitro test procedure are carried out to 
conclude the antioxidant properties of the sample. Among various free radical 
scavenging methods DPPH and ABTS assays was carried out in the present study. 
 
6.3.1 DPPH Radicalscavenging activity [1, 1-diphenyl-2-picrylhydrazyl (α,α-
diphenyl-β-picrylhydrazyl)] [58] 
The DPPH assay method is based on the reduction of DPPH, a stable free radical. The 
free radical DPPH with an odd electron gives a maximum absorption at 517nm (purple 
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colour). When antioxidants react with DPPH, which is a stable free radical becomes 
paired off in the presence of a hydrogen donor (e.g., a free radical- scavenging 
antioxidant) and is reduced to DPPH and a consequence the absorbance’s decreased from 
the DPPH radical to the DPPH-H form results in decolorization (yellow colour) with 
respect to the number of electrons captured. More the decolorization more is the 
reducing ability. Also the lower absorbance of the reaction mixture indicates higher free 
radical scavenging activity. This test has been most accepted model for evaluating the 
free radical scavenging activity of any new drug. 
(DPPH) + H-A → DPPH-H + A 
(Purple)             (Yellow) 
Procedure: 
0.3mM solution of DPPH in methanol was prepared and 1ml of this solution was added 
to 1ml of various concentrations of sample (10, 20, 40, 60, 80 and100 μg/ml) and the 
reference compound (5, 10, 15, 20, 25 and 30µg/ml), were shaken vigorously and left to 
stand in the dark at room temperature for 30min and then absorbance was measured at 
517nm. A control reaction was carried out without the test sample. Quercetin was used 
as standard and all the tests were performed in triplicate in order to get the mean values. 
The percentage of inhibition was calculated by comparing the absorbance values of the 
control and test samples. Antiradical activity was expressed as inhibition percentage (I 
%) and calculation using the following equation: 
Percentage inhibition (I %) = {(Abscontrol─Abssample )÷Abscontrol }x 100 
The different sample concentrations were used in order to obtain calibration curves and 
to calculate the EC50 values (EC50: concentration required to obtain a 50% radical 
scavenging activity).The IC 50 value was defined as the concentration (in µg/ml)of 
extracts that inhibits the formation of DPPH radicals by 50%. 
6.3.2 ABTS radical cation scavenging activity [59] 
Principle  
ABTS decolourization assay is an inhibition method. The peroxidase substrate 2, 2’- 
azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), forms a relatively stable 
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radical (ABTS+) upon one electron oxidation. This assay is based on the scavenging of 
light by ABTS radicals. An antioxidant with an ability to donate a hydrogen atom will 
quench the stable free radical and inhibits the absorption of the radical cation which has 
characteristic long-wavelength absorption spectrum showing maxima at 660,734, and 
820nm. The relatively stable ABTS radical has a green colour and is quantified 
spectrometrically at 734nm. 
Procedure  
ABTS radical scavenging activity of the extract was measured by Rice-Evans method. 
ABTS was dissolved in water to a 7mM concentration. ABTS radical cation (ABTS+) 
was produced by reacting ABTS stock solution with 2.45mM potassium persulfate and 
allowing the mixture to stand in the dark at room temperature for 12- 16 h before use. 
The radical was stable in this form for more than 2 days when stored in the dark at room 
temperature. For the study, ABTS solution was diluted with phosphate buffer saline pH 
7.4 (PBS) to an absorbance of 0.70 (± 0.02) at 734nm and equilibrated at 300C. After 
addition of 1ml of diluted ABTS solution to various concentrations of sample (1, 2, 4, 6, 
8, and 10 μg/ml) or reference compound (0.25, 0.5, 0.75, 1, 1.25 and 1.5 μg/ml) the 
reaction mixture was incubated for 6min and then absorbance was measured at 734 nm 
against a blank. A control reaction was carried out without the sample. All the tests were 
performed in triplicate in order to get the mean values. The percentage inhibition of 
ABTS+ by the sample was calculated according to the formula.  
Percentage inhibition (I %) = (Abs control- Abs sample /Abs control) X 100 
Different sample concentrations were used in order to obtain calibration curves and to 
calculate the IC50 values. (IC50 - concentration required to obtain a 50% radical 
scavenging activity). 
6.4 PHARMACOLOGICAL STUDY 
6.4.1 Animals and Diet 
Female wistar rats, weighing 150-200g were obtained from KMCH College of 
Pharmacy, Coimbatore. The animals were housed under controlled conditions of 
temperature (20-250C) and photoperiod 12-h light/dark cycle. All the rats were fed a 
pelletized commercial chow diet and fresh water ad libitum throughout the experimental 
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period, and weight gain measured weekly. All animal procedures were performed after 
approval from the ethics committee and accordance with the recommendations for the 
proper care and use of laboratory animals. 
6.4.2 TOCOLYTIC ACTIVITY 
Experimental design 
Thirty female wistar albino rats of 150-200 gm were used for the study. Rats were 
divided into five groups of 6 animals each. 
Table 3: Experimental design for oxytocin induced preterm labour 
 
GROUPS 
TREATMENT 
Group I Normal saline 
Group II Oxytocin (1 IU), i.m 
Group III Atosiban (6mg/kg),i.p 
Group IV AESC (200mg/kg), p.o 
Group V AESC (400mg/kg), p.o 
 
Procedure  
The rats were divided into five groups of six animals each. The group I was treated with 
normal saline, group II was treated with oxytocin (1 IU i.m) only, group III was treated 
with atosiban (6mg/kg), i.p, group IV and group V were treated with 200 and 400 mg/kg 
of AESC respectively. 
Requirements for obtaining vaginal smear: [60] 
Normal saline: The dropper needs only a small volume of normal saline (0.2–0.25ml) 
for flushing. Distilled water can also be used without markedly distorting the cells 
enough to impair identification. Only a drop or two needs to be placed on a slide.  
Slides: Microscopic slides can be used. 
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Microscope: A standard laboratory compound microscope is perfectly sufficient to 
evaluate a vaginal smear. 
Stain: 0.1% methylene blue. 
Procedure: [34], [60] 
The thirty (30) female rats were randomly distributed into 10 cages such that each cage 
contained 3 female rats. Each of the rats was identified with an indelible marker. After 
the distribution and identification of the female rats, a vaginal smear of each of them was 
made on a labelled clean glass slide.  
The smear was collected by carefully with droppers, although moistened cotton swabs 
have also been used. Dropper tips should be smooth and tapered. If a single dropper is 
used for more than one animal, it should be thoroughly rinsed between lavages to remove 
any residual cells from the dropper wall. When inserting the tip of the dropper into the 
vaginal orifice, it is important that the penetration be relatively shallow, approximately 
1cm.  
 Immediately after withdrawal from the vaginal cavity, the content was smeared onto a 
labelled clean glass slide. The smear was observed grossly to check for the presence of 
protein coagulates (remnants of the copulatory plug). 
After the initial smears were collected from the female rats, the male rats were 
introduced into 10 cages, such that the male: female ratio in these 10 cages was 1:3. 
After the introduction of males into the 10 mating cages, vaginal smears were made as 
described above for each of the females in all the 10 cages daily in the morning, and the 
smeared slides were observed grossly for protein coagulates. The observation of grossly 
visible protein coagulates on the vaginal smear of each female was recorded as evidence 
of mating. The mating was also confirmed by the presence of sperms in the vaginal 
smear. The sperm was observed by staining the smear with 0.1% methylene blue. 
The presence of sperm in the vaginal smear or observation of a vaginal plug indicates the 
occurrence of mating. The day that sperm is detected in the vaginal smear is designated 
as day 1 of gestation. After 10 days of gestation, the fetuses can be palpated, but 
palpation is more accurate after day 12. By day 13 of gestation, the abdominal 
enlargement is visible, and mammary development and nipple enlargement can be 
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observed on day 14 of gestation. Once the protein coagulates and sperms were observed 
on the vaginal smear of each rat, the rat was thereafter weighed at four-day intervals to 
check the progress of the pregnancy. 
6.4.3 IN VIVO ANTIOXIDANT ACTIVITY  
Blood Collection 
After the end of the treatment period the animals were anaesthetized with diethyl ether 
(inhalation) and its blood was collected by retro orbital puncture without adding EDTA. 
Separation of serum [61] 
The serum was prepared using a standard method. Briefly, the method used is as follows. 
The blood was allowed to clot for 30 minutes and then centrifuged at 2500rpm for 15 
minutes and serum was harvested. 
ESTIMATION OF TOTAL PROTEIN [62] 
Total protein content of the sample was determined by following method: 
Requirements 
Alkaline copper reagent 
 Solution A: 2% sodium carbonate in 0.1 N NaOH.  
 Solution B: 0.5% copper sulphate in 1% sodium potassium tartarate 
 Solution C: 50 ml of solution A was mixed with 1 ml of solution B just 
before use. 
 Folin’s phenol reagent (commercial reagent, 1:2 dilutions) Bovine serum 
albumin (BSA).  
Principle:  
This method involves two steps; Step 1: Protein binds with copper in alkaline medium 
and reduces it into Cu++. Step 2:  The Cu++ formed catalyses the oxidation reaction of 
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aromatic amino acids by reducing phosphomolybdo tungstate to heteropolymolybdanum, 
which leads to the formation of blue colour and absorbance was measured at 640 nm.  
Procedure: 
 0.1 ml sample was made up to 1 ml with distilled water. 5 ml of alkaline solution was 
added, mixed well and allowed to stand for 10 min. Then, 0.5 ml Folin’s reagent was 
added, mixed well and incubated at room temperature for another 10 min. The blue 
colour developed was measured at 640 nm against blank. Bovine serum albumin (1 
mg/ml) served as the standard and from the standard graph obtained the amount of 
protein in the sample was calculated. 
6.4.3.1 Enzymatic antioxidant activity 
6.4.3.1.1 Estimation of superoxide dismutase (SOD) [63] 
Requirements 
 Adrenaline 
 Carbonate Buffer (pH – 10.2) 
 0.1mM EDTA 
Principle 
Superoxide dismutase is an endogenous enzymatic antioxidant which catalyzes the 
dismutation of superoxide free radical. This method is based on the inhibition of the 
spontaneous oxidation of the adrenaline to adrenochrome by the enzyme superoxide 
dismutase. 
Procedure 
To 0.5 ml of the sample, 1.5 ml of carbonate buffer and 0.5 ml of 0.1mM EDTA was 
added and mixed. To this 0.4 ml of adrenaline was added at the time of measurement of 
the optical density at 480 nm. The antioxidant activity of SOD enzyme was expressed as 
units/min/mg protein. 
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6.4.3.1.2 Estimation of Catalase (CAT) [64] 
Requirements 
 Dichromate acetic acid reagent 
 0.01M Phosphate Buffer (pH – 7.0) 
 0.2M Hydrogen peroxide 
Principle 
The normal antioxidant activity of the enzyme catalase is to accelerate the decomposition 
of hydrogen peroxide to water and oxygen. This method is based on the principle of 
measuring the rate of decomposition of hydrogen peroxide by the enzyme Catalase, 
which was measured spectrophotometrically at 570nm, since hydrogen peroxide has the 
absorbance at this range. 
Procedure 
To 1 ml of sample, 4ml of hydrogen peroxide and 5 ml of phosphate buffer was added 
and mixed. From this 1ml of solution was taken and mixed with dichromate acetic acid 
reagent and allowed to incubate for 30 minutes at room temperature. The absorbance was 
measured at 570 nm. The activity of Catalase was expressed as µmole of H2O2 
consumed/min/mg protein. 
6.4.3.2 Non Enzymatic anti-oxidant activity 
6.4.3.2.1 Estimation of reduced glutathione (GSH) activity [65] 
Requirements 
 5% TCA 
 0.6mM 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) in 0.2 M sodium phosphate 
 0.2 M Phosphate buffer at pH 8.0 
Principle 
DTNB is a disulfide compound, which was reduced by sulfhydryl groups present in 
GSH. This reduction leads to formation of yellow colour, which was measured at 412nm. 
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Procedure 
To 1ml of the sample, 1 ml of TCA solution was added and centrifuged. The supernatant 
was collected and the precipitate formed was removed. To 0.5 ml of supernatant 2 ml 
DTNB was added, the volume was made up to 3 ml with phosphate buffer. Then 
absorbance was read at 412nm. The amount of glutathione was expressed as µg/mg 
protein. 
6.4.3.3 Determination of lipid peroxidation (LPO) [66] 
Requirements 
 Thiobarbituric acid 0.37% 
 0.25 N HCL 
 15% TCA 
Principle 
This assay is based on the reaction between thiobarbituric acid with malonyldialdehyde 
which is a formed as a result of polyunsaturated fatty acid oxidation. This reaction leads 
to the formation of pink colored TBA-MDA complex which is measured at 532 nm. 
Procedure 
To 0.1 ml of sample, 2ml of TBA-TCA-HCL reagent (ratio of 1:1:1) was added, mixed 
and kept in a water bath for 15 minutes. Afterwards the solution was cooled and 
supernatant was removed and absorbance was measured at 535 nm against reference 
blank. The level of lipid peroxides was given as moles of MDA formed/mg protein. 
6.4.4 IN VITRO STUDY OF ISOLATED RAT UTERUS [67], [68], [44] 
Female non-pregnant wistar rats were pretreated subcutaneously with estradiol valerate 
0.1 mg/kg of 24 h prior to the actual experiment for uterine sensitization. The rats were 
killed by cervical dislocation and exsanguinations. The abdomen was opened and the two 
horns of the uterus carefully isolated, freed of mesenteric fat and a strip of the horn about 
1 - 2 cm was cut out. A thread was then attached to one end of the isolated strip of uterus 
and was tied to the aerator tube in the organ bath containing 25 ml De Jalon’s 
physiological salt solution having the following chemical composition: NaCl-9 g/L, 
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NaHCO3 - 0.5 g/L, D-glucose - 0.5 g/L, KCl-0.402 g/L, CaCl2˟2 H2O -0.08 g/L. Another 
thread was attached to the other end of the isolated uterus and fixed to a lever system. 
The tissue was aerated and temperature was maintained at 30-32OC, with a pH of 7.4.  
The tissue was allowed to equilibrate for 30 min before the start of the experiment. A 
lever system was used to record the uterine contractions and relaxations on a smoked 
glossy paper in kymograph drum, moved at 2.5mm/sec speed which was varnished after 
and calculated the data. The response of uterine tissue to oxytocin (0.01 IU/ml) before 
and after incubation with aqueous seed extract of Syzygium cumini (25 and 50 mg/ml) for 
one minute were recorded along with standard drug atosiban (5 mg/ml). 
6.5 STATISTICAL ANALYSIS 
Data were analyzed by one way ANOVA followed by Tukey’s multiple comparison test 
using Graphpad 5.0 software. The values were expressed as Mean ± SEM.  
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7. RESULTS 
 
7.1 EXTRACTIVE YIELD 
Percentage Yield of AESC 
Coarsely powdered seeds of Syzygium cumini were extracted with water and the 
percentage yield was found to be 14.5% w/w. 
7.2 PRELIMINARY PHYTOCHEMICAL ANALYSIS 
Table 4: Qualitative Chemical Tests 
 
+= Present, ++ = More present 
 
 
Sl.No Phytochemical Constituents AESC. 
1 Carbohydrates + 
2 Alkaloids + 
3 Glycosides + 
4 Triterpenoids + 
5 Flavonoids ++ 
6 Phenols ++ 
7. Tannins + 
7 Steroids and sterols + 
8 Saponins + 
9 Proteins and amino acids ++ 
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7.3 QUANTIFICATION OF TOTAL PHENOL AND FLAVONOIDS 
Table 5: Estimation of total phenolic content of AESC 
Sample Concentration (µg/ml) Absorbance at 725 nm 
Standard  
(Gallic Acid) 
 
 
 
10 0.087 
20 0.118 
40 0.205 
60 0.336 
80 
 
0.401 
100 0.495 
AESC 
 
100 0.2494 
 
Figure 6: Standard graph for Gallic acid for the estimation of total phenolic content 
 
 
The total Phenol content present in AESC was found to be 54.1mg/g equivalent to gallic 
acid. 
 
 
0.087
0.118
0.205
0.336
0.401
0.495
y = 0.0047x + 0.033
R² = 0.9931
0
0.1
0.2
0.3
0.4
0.5
0.6
0 20 40 60 80 100 120
A
B
S
O
R
B
A
N
C
E
CONCENTRATION (µg/ml)
GALLIC ACID
Linear (GALLIC ACID)
                                                                                                       Results 
                           
Department of Pharmacology                                                       Page 55   
 
 
Table 6: Estimation of total flavonoid content of AESC 
Sample Concentration (µg/ml) Absorbance at 415nm 
Standard  
(Quercetin) 
 
 
 
10 0.1150 
20 0.2150 
40 0.4160 
60 0.6579 
80 
 
0.9571 
100 1.1135 
AESC 
 
100 0.5362 
 
Figure 7: Standard graph of quercetin for the estimation of total flavonoid content 
 
 
The total flavonoid content in AESC was found to be 50.1 mg/g of extract calculated as 
Quercetin equivalent. 
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7.4 IN VITRO ANTI OXIDANT STUDY 
 
7.4.1 DPPH RADICAL SCAVENGING ACTIVITY 
 
Table 7: Percentage inhibition and IC50 values of DPPH radical by quercetin and 
AESC 
Sample   
 
Concentration 
(μg/ml) 
% Inhibition 
IC50 
(μg/ml) 
Standard 
(Quercetin) 
5 
32.20 
10.79 
10 42.14 
15 53.36 
20 68.33 
25 86.65 
30 94.56 
AESC 
10 26.63 
33.15 
20 38.70 
40 48.21 
60 57.33 
80 74.22 
100 85.12 
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Figure 8: DPPH radical scavenging activity of quercetin 
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Figure 9: DPPH radical scavenging activity of AESC 
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7.4.2 ABTS RADICAL SCAVENGING ACTIVITY 
Table 8: Percentage inhibition of ABTS radical by quercetin and AESC 
Sample   
 
Concentration 
(μg/ml) 
% Inhibition 
IC50 
(μg/ml) 
Standard 
(Quercetin) 
0.25 42.56 
0.3869 
0.5 50.34 
0.75 65.12 
1.0 79.84 
1.25 90.23 
1.5 96.41 
AESC 
1 19.43 
4.43 
2 27.82 
4 39.9 
6 53.12 
8 70.24 
10 83.56 
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Figure 10: ABTS radical scavenging activity of quercetin 
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Figure 11: ABTS radical scavenging activity of AESC 
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7.5 TOCOLYTIC ACTIVITY 
Table 9: Effects OF AESC and atosiban on oxytocin induced preterm labour on rat 
model 
Group 
Total 
number 
of rats 
Numbers of rat delivered 
Rates of 
term 
delivery 
Delivery day 
(Mean±SEM) 
Preterm Term 
D
a
y
 1
7
 
D
a
y
 1
8
 
D
a
y
 2
1
 
D
a
y
 2
2
 
D
a
y
 2
3
 
Normal 6 0 0 0 0 6 100 23±0 
Control  
(oxytocin 1 IU, 
i.m) 
6 4 2 0 0 0 0 17.3±0.210*** 
Control+ 
Atosiban 
(6mg/kg, i.p) 
6 0 0 0 3 3 100 22.5±0.223*** 
Control+ 
AESC 
(200mg/kg,p.o) 
6 0 0 2 2 2 66.6 22±0.365*** 
Control+ 
AESC 
(400mg/kg,p.o) 
6 0 0 1 1 4 83.3 22.5±0.341*** 
  
Statistical comparison: values represent mean ± SEM, n=6. Statistical analysis was 
done by one way analysis of variation (ANOVA) followed by Tukey’s multiple 
comparison test. ***P<0.001, denotes comparison of oxytocin control group with normal 
and all other groups were compared with oxytocin control group. 
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Figure 12: Effect of AESC on preterm labour 
 
              Sperm                                           
Figure 13: Microscopical examination (100x) of vaginal smear of mated animal 
showing sperms 
 
 
 
                                                                                                       Results 
                           
Department of Pharmacology                                                       Page 62   
 
 
7.6 INVIVO ANTIOXIDANT STUDY 
Table 10: Effect of AESC on enzymatic and non enzymatic antioxidant levels 
GROUP 
 
Total 
protein 
(mg/dl) 
SOD  
(Unit/  mg 
protein) 
 
CAT 
( μmol of 
H2O2 
consumed/  
mg protein) 
 
GSH 
(Glutathione 
μg/mg 
LPO 
(nmol of 
MDA/mg 
protein) 
 
Normal 
 
3.9±0.08 7.4±0.24 
 
53.3±0.37 12.8±0.09 2.8±0.09 
 
Control 
oxytocin (1 IU) 
9.8±0.44*** 2.4±0.19*** 28.4±0.36*** 
 
6.7±0.19*** 8.8±0.11*** 
Control+ 
Atosiban(6mg/kg) 
2.6±0.54*** 5.84±0.13*** 
 
31.75±0.88** 
 
11.9±0.10*** 
 
3.7±0.16*** 
 
Control+ 
AESC(200mg/kg) 
 
4.8±0.21** 3±0.02ns 
 
31.07±0.38* 
 
7.52±0.23* 
 
6.8±0.09*** 
 
Control+ 
AESC(400mg/kg) 
3.9±0.04*** 3.36±0.24* 
 
32.05±0.65** 
 
11.8±0.122*** 
 
5.9±0.02*** 
 
 
Statistical comparison: values represent mean ± SEM, n=6. Statistical analysis was 
done by one way analysis of variation (ANOVA) followed by Tukey’s multiple 
comparison test. *P<0.05, **P<0.01, ***P<0.001 and ns- non significant, denotes 
comparison of oxytocin control group with normal and all other groups were compared 
with oxytocin control group. 
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Figure 14: Effect of AESC on serum total protein 
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Figure 15: Effect of AESC on serum SOD 
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Figure 16: Effect of AESC on serum CAT 
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Figure 17: Effect of AESC on serum GSH 
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Figure 18: Effect of AESC on serum LPO 
 
Statistical comparison: values represent mean ± SEM, n=6. Statistical analysis was 
done by one way analysis of variation (ANOVA) followed by Tukey’s multiple 
comparison test. *P<0.05, **P<0.01, ***P<0.001 and ns- non significant, denotes 
comparison of oxytocin control group with normal and all other groups were compared 
with oxytocin control group. 
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7.7 INVITRO STUDY OF ISOLATED RAT UTERUS 
Table 11: Effect of AESC on oxytocin induced contraction in rat uterus 
Group Drug Concentration Height of 
Contractions(cm) 
% 
Inhibition 
I 
 
oxytocin 0.01 IU/ml 
5.5 ˗ 
II AESC 
extract + 
oxytocin 
25 mg/ml + 
0.01 IU/ml 2.7 50.9 
III AESC 
extract + 
oxytocin 
50 mg/ml + 
0.01 IU/ml 1.5 72.7 
IV Atosiban + 
oxytocin 
5 mg/ml + 
0.01 IU/ml 
0.57 89.6 
 
 
Figure 19: Effect of AESC and Atosiban on isolated rat uterus 
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8. DISCUSSION 
Preterm birth is the most common cause of neonatal morbidity and mortality 
world- wide .Almost 75% of perinatal deaths occur in infants born before 37 weeks 
gestation [69]. 
The rationale for treating preterm labour is to reduce perinatal morbidity and 
mortality by increasing the gestational age at delivery. Assuming tocolysis is beneficial, 
the choice of drug remains controversial. Magnesium sulphate, calcium channel 
blockers, prostaglandin synthase inhibitors, nitric oxide donors, β-sympathomimetics and 
oxytocin antagonists have all been suggested to be effective. Given the problems of 
efficacy and adverse effects with each tocolytic, particularly in view of the potentially 
devastating consequences of preterm delivery, it is not surprising that new drugs have 
been developed and tested in clinical trials [70]. 
The study aims at the evaluation of the tocolytic activity of aqueous seed extract 
of Syzygium cumini on oxytocin induced preterm labour as well as its antioxidant 
property. 
The preliminary phytochemical screening of AESC were performed and the 
results revealed the presence of carbohydrates, flavonoids, triterpenoids, phenols, 
glycosides, tannins, steroids, alkaloids, saponins, proteins and amino acids. The various 
phytoconstituents present in the extract is shown in the Table 4. 
Phenolics and flavanoid normally scavenge the free radicals and play an essential 
role in prevention and therapy of PTL, and many more diseases by inducing antioxidant 
defense system, drug metabolizing enzymes, modulating diverse events in cellular level 
and inhibiting inflammation, hyperplasia, proliferation and oxidative DNA damage. Poly 
phenolic compounds (quercetin, gallic acid, rutin) are natural antioxidants which 
decreases oxidation of bio molecules essential for life [71]. The total Phenol content 
present in Syzygium cumini seed extract was found to be 54.1 mg/g equivalent to gallic 
acid. The total flavanoid content in AESC was found to be 50.1 mg/g of extract 
calculated as Quercetin equivalent. 
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Herbal drugs containing radical scavengers are gaining importance in treating 
oxidative stress related diseases. [72] DPPH radical scavenging activity of the extract at 
different concentration was compared with the standard quercetin. Smaller IC50 value 
indicates a higher antioxidant potential. The IC50 value of the standard and test extract 
was found to be 10.79 µg/ml and 33.15µg/ml respectively. The higher IC50 values of the 
sample indicated lesser scavenging activity of the sample when compared with the 
standard. The study showed the promising radical scavenging activity of the extract due 
to hydrogen-donating ability of the extract. 
The ability of the extract to donate hydrogen atoms or electrons to scavenge the 
radical cation was reflected by the decolourization of ABTS radical cation. The radical 
scavenging activity of the extract was compared with that of the standard and the IC50 
values obtained were 0.3869µg/ml and 4.43µg/ml for standard and extract respectively. 
Premature labour still a health challenge world-wide, thus huge efforts were done 
and required to found a solution for it, this work was an attempt to find a natural 
solution.   
However, the efficacy and safety of tocolytics are not adequate, new agents are 
therefore required including substances from natural sources. [1] 
In the current study, a significant increase in the in the rate of preterm delivery of 
the control animals was observed when compared with the normal group. The AESC 
treated group has showed a significant reduction in the rate of preterm delivery which 
was comparable with the standard treated group as well as the normal group.  
Living organisms have developed several effective mechanisms to get protection 
from the reactive oxygen species. The antioxidant defense mechanisms of the body 
include enzymes such as SOD, GSH, CAT and GPx.  
In the present study it was observed that there was a crucial depletion of the 
activity of all the enzymes and a marked rise of lipid peroxidation. The study reveals that  
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the extracts have been able to increase the endogenous antioxidant enzyme activities 
while reducing the lipid peroxidation. 
The cells containing Super Oxide Dismutase enzyme scavenges superoxide ion 
and prevents its accumulation so that cells are protected from oxidative stress. SOD 
catalyses this dismutation of superoxide in which one O2* is oxidized to O2 while the 
other is reduced to H2O2. The formed H2O2 is able to damage the cellular components 
and are instantly removed by enzymes like catalase and GPx. A significant decrease in 
SOD levels was observed in control (oxytocin) rats when compared to normal rats. The 
levels get increased in the rats treated with both low dose (200 mg/kg) and high dose 
(400mg/kg) of AESC when compared to SOD levels in control rats.  
Oxidative stress has a major role in preterm labour. The catalase enzyme is an 
endogenous antioxidant enzyme that neutralizes reactive oxygen species by converting 
H2O2 into H2O and O2. Among the other antioxidant enzymes, including superoxide 
dismutase and glutathione peroxidase, catalase is an elementary defense against 
oxidative stress. In oxytocin control rats, a significant decreased level of catalase was 
observed as compared to normal rats. The low dose (200 mg/kg) and high dose 
(400mg/kg) of AESC treated groups showed significant increase in catalase levels when 
compared to control rats.  
Reduced Glutathione prevents free radical induced oxidation of SH groups of 
various proteins to disulfide derivatives. It also protects haemoglobin from getting 
oxidized by H2O2. A significant decrease in the GSH levels was observed in the control 
rats when compared to normal control rats. Rats treated with both low dose (200 mg/kg) 
and high dose (400mg/kg) of AESC showed significantly higher GSH levels when 
compared to control rats [24], [25]. 
Lipid peroxidation indicates the oxidative degradation of lipids in which the free 
radicals steals electrons from the lipids in the cell membrane and leads to cell damage. 
This process proceeds by a free radical chain reaction mechanism. Radical reaction 
consists of initiation, propagation and termination processes. A significant increased 
level of LPO was observed in the control rats when compared to normal control rats. The  
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low dose (200 mg/kg) and high dose (400mg/kg) of AESC treated rats showed 
significant decreased LPO levels when compared to control rats. 
The uterus is spontaneously active, which means that, with or without any 
nervous/hormonal stimulation, a piece of isolated, pregnant or non- pregnant, uterus will 
produce regular spontaneous contractions. [2] 
The results of Invitro study showed that the aqueous extract of Syzygium cumini 
at 25 mg/ml and 50 mg/ml produced significant inhibition of oxytocin, induced 
contractions of the uterine smooth muscle in non pregnant rats. 
It is envisaged that the active ingredients (compounds) will have a potential for 
being added to the present list of tocolytic agents used clinically. To improve the safety 
of this traditional herbal remedy, additional research is needed to define the stability and 
bioactivity of this product. Therefore, further studies are needed for the isolation and 
characterization of the active constituents. 
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9. CONCLUSION 
Syzygium cumini Linn (family Myrtaceae) is a well known bioactive plant in Ayurvedic 
system of medicine. The present investigation was aimed at determining the tocolytic 
activity of aqueous seed extract of Syzygium cumini. 
AESC showed significant invitro antioxidant activity by terminating the actions of free 
radicals. The extract was studied for its tocolytic activity using oxytocin induced preterm 
labour in which atosiban (6mg/kg) was used as the standard.  
The study revealed that the aqueous extract of Syzygium cumini seed possesses 
significant tocolytic activity which was evident with reduction in the incidence of 
preterm delivery. 
AESC showed tocolytic activity that is mediated by its effects on rates of preterm 
delivery, anti-oxidant (SOD, CAT, GSH and, LPO), and invitro studies. The aqueous 
extract of S.cumini possesses tocolytic activity probably due to the presence of active 
constituents present in the extract. In vitro studies of AESC significantly inhibited the 
frequency and amplitude of spontaneous uterine contractions on the isolated non 
pregnant rat uterus preparations. 
Hence, from the present study it can be concluded that the AESC has the 
potential to prevent preterm delivery as well as it can reduce the complications of the 
same. It seems promising that these data obtained from the study can be further validated 
in the future studies which eventually can be developed as a formulation that offers a 
high degree of protection from preterm delivery. 
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